Details of the Drug

General Information of Drug (ID: DM58WKG)

Drug Name
Panobinostat
Synonyms
Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
Indication
Disease Entry ICD 11 Status REF
Chronic graft versus host disease N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Multiple myeloma 2A83 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Primary cutaneous T-cell lymphoma N.A. Approved [1]
Type-2 diabetes 5A11 Phase 3 [3]
Primary myelofibrosis 2A20.2 Phase 2 [3]
⏷ Show the Full List of Indication(s)
Affected Organisms
Humans and other mammals
ATC Code
L01XH03: Panobinostat
L01XH: Histone deacetylase (HDAC) inhibitors
L01X: OTHER ANTINEOPLASTIC AGENTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 349.4
Logarithm of the Partition Coefficient (xlogp) 3
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2 h []
Clearance
The drug present in the plasma can be removed from the body at the rate of 10.2 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 30 hours [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.1% [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Cerebrovascular disorder Not Available NAA15 OT53SIZG [5]
Platelet aggregation Not Available CBS OT46FSKD [5]
Platelet aggregation Not Available MTHFR OTUBJSR7 [5]
Chemical Identifiers
Formula
C21H23N3O2
IUPAC Name
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
Canonical SMILES
CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO
InChI
InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
InChIKey
FPOHNWQLNRZRFC-ZHACJKMWSA-N
Cross-matching ID
PubChem CID
6918837
ChEBI ID
CHEBI:85990
CAS Number
404950-80-7
UNII
9647FM7Y3Z
DrugBank ID
DB06603
TTD ID
D0E3SH
VARIDT ID
DR00181
INTEDE ID
DR1234
ACDINA ID
D00507
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase 1 (HDAC1) TT6R7JZ HDAC1_HUMAN Inhibitor [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 (PLCE1) OTJISZOX PLCE1_HUMAN Gene/Protein Processing [9]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Gene/Protein Processing [9]
2-hydroxyacylsphingosine 1-beta-galactosyltransferase OT17ST61 CGT_HUMAN Gene/Protein Processing [9]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D) OT1RWFV0 PDE4D_HUMAN Gene/Protein Processing [9]
3-hydroxy-3-methylglutaryl-CoA lyase, cytoplasmic (HMGCLL1) OT9SQ5PU HMGC2_HUMAN Gene/Protein Processing [9]
4-aminobutyrate aminotransferase, mitochondrial (ABAT) OTXAGR7J GABT_HUMAN Gene/Protein Processing [9]
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase 9 (FUT9) OTLIJBQY FUT9_HUMAN Gene/Protein Processing [9]
4-hydroxyphenylpyruvate dioxygenase-like protein (HPDL) OTW7D1SV HPDL_HUMAN Gene/Protein Processing [9]
A disintegrin and metalloproteinase with thrombospondin motifs 15 (ADAMTS15) OTYB6JS3 ATS15_HUMAN Gene/Protein Processing [9]
A disintegrin and metalloproteinase with thrombospondin motifs 19 (ADAMTS19) OTEG5Q2G ATS19_HUMAN Gene/Protein Processing [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Chronic graft versus host disease
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histone deacetylase 1 (HDAC1) DTT HDAC1 6.73E-02 0.24 0.59
P-glycoprotein 1 (ABCB1) DTP P-GP 2.55E-01 4.83E-01 5.66E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.10E-01 -1.23E-01 -2.88E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 49 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC1 1.2114 6.7164 -2.3839 14.4138
SK-N-MC CTRP2 -7.5377 -7.0595 -7.5377 90.484
TC71 CTRP2 -7.3845 -5.185 -7.3845 88.2159
EW-13 GDSC1 -7.1394 -4.6594 -7.1433 84.1553
EW-22 GDSC1 -6.7903 -4.9366 -6.7908 82.9713
A-673 CTRP2 -6.6962 2.1556 -7.0235 73.8978
U2OS CTRP2 -6.6607 3.0064 -7.1254 72.5989
NOS-1 [Human HNSCC] GDSC1 -6.5982 -5.2834 -6.5982 82.1808
EW-18 GDSC1 -6.5061 -4.483 -6.5076 79.6184
MHH-ES-1 CTRP2 -6.1875 -4.2057 -6.1875 81.2208
ES7 GDSC1 -6.1146 -3.5648 -6.1262 74.2535
ES8 GDSC1 -6.0738 -3.7713 -6.08 74.3952
HuO9 GDSC1 -5.9914 -4.4624 -5.9916 74.8261
NY GDSC1 -5.9078 -4.026 -5.9094 73.3583
EW-7 GDSC1 -5.8665 -3.8537 -5.8694 72.6743
ES1 GDSC1 -5.6317 -3.3471 -5.6406 69.5713
EW-3 GDSC1 -5.6267 -3.5602 -5.6312 69.8505
MHH-ES-1 GDSC1; CCLE -5.5634 -3.984 -5.5634 73.4601
SK-ES-1 CTRP2 -5.3594 -1.4204 -5.3656 74.4952
U2OS GDSC1; CCLE -5.335 -2.9404 -5.3361 71.1485
SK-ES-1 GDSC1; CCLE -5.333 -3.1255 -5.3335 71.2538
CADO-ES1 GDSC1 -5.2087 -2.9238 -5.222 64.7336
SK-PN-DW GDSC1 -5.1868 -2.8328 -5.2031 64.3996
EW-16 GDSC1 -5.1793 -3.204 -5.1848 64.7078
SW1353 CTRP2 -4.8709 -2.532 -4.8709 72.5695
SaOS-2 GDSC1; CCLE -4.8089 -3.2964 -4.8089 67.0418
TC-71 GDSC1; CCLE -4.7657 -3.4209 -4.7657 66.6844
HOS GDSC1; CCLE -4.6449 -1.9022 -4.6504 65.2529
CHSA8926 GDSC1 -4.4424 -3.3477 -4.4426 55.9536
ES4 GDSC1 -4.3424 0.9229 -5.0114 53.2118
CAL-78 GDSC1; CCLE -4.0911 -1.523 -4.0965 60.7212
SW1353 CCLE -3.9598 -2.5892 -3.9598 59.7697
CAL-78 CTRP2 -3.8576 1.5351 -3.9429 64.3326
SaOS-2 CTRP2 -3.7668 -1.5896 -3.7669 65.3293
A-673 GDSC1; CCLE -3.5536 -0.0033 -3.6087 55.9403
HuO-3N1 GDSC1 -3.1518 0.2386 -3.5007 41.2955
EW-24 GDSC1 -2.9951 -0.4447 -3.1544 38.6975
MG-63 GDSC1; CCLE -2.9588 1.1155 -3.1022 51.0779
SJSA-1 CTRP2 -2.9051 2.9883 -3.0894 58.4729
SJSA-1 GDSC1; CCLE -2.8428 0.1862 -2.882 50.1743
CAL-72 GDSC1 -2.7009 0.2561 -3.0141 35.9266
Hs 888.T CTRP2 -2.3892 3.5451 -2.6172 55.4506
ES6 GDSC1 -2.1846 2.4679 -3.3099 34.0199
MG-63 CTRP2 -0.7685 6.405 -1.4923 46.2346
HOS CTRP2 -0.7549 4.3063 -0.9838 45.6511
G-292 clone A141B1 CTRP2 -0.0021 9.2312 -1.6336 43.1069
G-292 clone A141B1 GDSC1 0.0764 14.2703 -7.0487 35.2736
EW-1 GDSC1 0.4242 6.7369 -2.9979 20.6519
Hs 822.T CTRP2 4.2037 10.5332 2.1279 20.1997
⏷ Show the Full List of 49 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 324 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MEC1 CTRP2 -7.2315 -5.6031 -7.2315 87.9922
JK1 CTRP2 -6.9294 -4.4971 -6.9295 85.3461
JM1 CTRP2 -8.9379 -7.0467 -8.9379 95.9316
JM1 GDSC1 -6.5815 -5.1196 -6.5815 81.7182
EoL-1 CTRP2 -14.3838 -2.1726 -14.6584 89.0753
GA-10 CTRP2 -9.7288 0.5165 -10.0352 81.9427
KMS-26 CTRP2 -9.6886 -7.6417 -9.6886 97.65
Kasumi-1 CTRP2 -9.4304 -7.0318 -9.4304 96.3432
SK-MM-2 CTRP2 -9.3027 11.78 -12.5587 68.565
Daudi CTRP2 -9.0278 -5.4956 -9.0281 92.7819
MOLP-8 CTRP2 -9.0264 -6.7389 -9.0264 95.3915
SEM CTRP2 -8.9431 -7.6991 -8.9431 97.3091
A4/Fukuda CTRP2 -8.8498 -7.0078 -8.8498 95.7291
OCI-AML-3 CTRP2 -8.8288 -7.722 -8.8288 97.1866
OPM-2 CTRP2 -8.7933 1.2386 -9.1344 79.4936
SET-2 CTRP2 -8.7712 -7.0349 -8.7712 95.6628
NU-DUL-1 CTRP2 -8.736 -7.8377 -8.736 96.8267
H9 GDSC1 -8.6983 -6.6038 -8.6985 95.4615
ST486 CTRP2 -8.645 -6.9127 -8.645 95.1826
KMS-12-BM CTRP2 -8.6298 -6.8424 -8.6298 95.0096
MOTN-1 CTRP2 -8.6033 -6.742 -8.6033 94.7526
SU-DHL-16 GDSC1 -8.5637 -7.1673 -8.5637 97.3821
OPM-2 GDSC1; CCLE -8.5001 -4.209 -8.5109 87.7919
BCP-1 CTRP2 -8.4358 -7.1538 -8.4358 95.1525
DoHH2 CTRP2 -8.418 -4.7978 -8.4185 90.4176
EJM CTRP2 -8.3743 -5.1283 -8.3745 91.0123
LC4-1 GDSC1 -8.3372 -6.3332 -8.3374 94.1855
Karpas-45 GDSC1 -8.3066 -6.1196 -8.307 93.3274
MHH-CALL-4 CTRP2 -8.2771 -6.138 -8.2771 92.8127
Kasumi-2 CTRP2 -8.228 -6.8916 -8.228 94.0301
KMS-21-BM CTRP2 -8.2069 -6.7364 -8.2069 93.7005
MOLT-13 GDSC1 -8.1465 -6.4298 -8.1466 94.2953
SUP-B15 CTRP2 -8.1444 -6.8144 -8.1444 93.6041
CML-T1 GDSC1 -8.1444 -6.7123 -8.1444 95.3929
OCI-Ly19 CTRP2 -8.1442 -5.3349 -8.1442 90.9268
RCH-ACV GDSC1 -8.1068 -6.606 -8.1068 94.9178
LP-1 CTRP2 -8.0959 -6.3172 -8.0959 92.6203
KMS-34 CTRP2 -8.0418 -6.4654 -8.0418 92.6796
KMS-20 CTRP2 -8.0091 -3.3201 -8.015 86.6238
MOLT-13 CTRP2 -8.0073 -6.3022 -8.0073 92.2947
Mino CTRP2 -7.9885 -6.6131 -7.9885 92.6945
Karpas-231 GDSC1 -7.9774 -6.4254 -7.9774 93.9525
HPB-ALL CTRP2 -7.9691 -6.3242 -7.9691 92.191
Pfeiffer CTRP2 -7.9453 -4.1556 -7.9463 88.1438
M-07e CTRP2 -7.9443 -7.0165 -7.9443 92.9551
HuT 78 CTRP2 -7.918 -4.6095 -7.9183 88.962
OCI-Ly3 CTRP2 -7.9176 -6.0184 -7.9176 91.5174
KO52 CTRP2 -7.9053 -6.0173 -7.9053 91.4726
P30/OHK GDSC1 -7.8951 -6.4033 -7.8951 93.6641
DB CTRP2 -7.8893 -6.6701 -7.8893 92.3319
SUP-B15 GDSC1 -7.7799 -6.4073 -7.7799 93.3395
JSC-1 GDSC1 -7.7393 -6.2489 -7.7393 92.5899
HL-60 CTRP2 -7.7374 -6.8777 -7.7374 91.706
ALL-PO GDSC1 -7.7374 -5.7803 -7.7377 90.7657
BL-70 CTRP2 -7.6665 -6.5983 -7.6665 91.1278
MM1.S CTRP2 -7.6514 -5.516 -7.6514 89.7544
KMS-11 CTRP2 -7.6463 -4.5339 -7.6465 88.0755
MY-M12 GDSC1 -7.6439 -6.0746 -7.644 91.5753
KMS-26 CCLE -7.6275 -5.7149 -7.6275 89.2464
F-36P CCLE -7.6214 -5.4159 -7.6215 88.5615
SU-DHL-6 CTRP2 -7.5917 -5.7168 -7.5917 89.8098
MOLM-13 CTRP2 -7.5895 -6.3977 -7.5895 90.5562
NU-DUL-1 GDSC1 -7.5831 -6.2797 -7.5831 92.0894
SIG-M5 CTRP2 -7.5782 -7.1286 -7.5782 90.7542
NB4 GDSC1 -7.5772 -6.3577 -7.5772 92.3459
Karpas-422 CTRP2 -7.5734 -4.5828 -7.5735 87.9393
MV4-11 CTRP2 -7.5651 -5.7668 -7.5651 89.7629
OCI-AML-5 CTRP2 -7.5638 -6.1264 -7.5638 90.1763
TALL-1 [Human adult T-ALL] CTRP2 -7.5445 -2.6903 -7.5539 84.3462
Granta-519 CTRP2 -7.5091 -4.5146 -7.5092 87.6154
CMK CTRP2 -7.4748 -7.0963 -7.4748 90.0668
JeKo-1 CTRP2 -7.4748 -6.9444 -7.4748 90.0632
QIMR-WIL GDSC1 -7.4739 -4.7144 -7.4802 85.7845
OCI-M1 CTRP2 -7.4733 -6.9721 -7.4733 90.055
JJN-3 CTRP2 -7.4411 -4.19 -7.4414 86.8351
Ri-1 CTRP2 -7.4407 -5.1214 -7.4407 88.3508
ST486 GDSC1 -7.426 -5.9139 -7.426 90.0186
MV4-11 GDSC1 -7.4257 -6.4367 -7.4257 91.7673
KE-37 CTRP2 -7.4177 -6.8101 -7.4177 89.6798
CA46 GDSC1 -7.3796 -5.9871 -7.3796 90.0267
P12-Ichikawa CTRP2 -7.3723 -6.8379 -7.3723 89.3815
Mono-Mac-1 CTRP2 -7.3695 3.6822 -8.0239 73.2862
HEL 92.1.7 CTRP2 -7.3678 -7.0225 -7.3678 89.3538
NK-92MI GDSC1 -7.3321 -5.8068 -7.3321 89.151
MOLT-16 CTRP2 -7.3226 -5.8448 -7.3226 88.6796
Ki-JK CTRP2 -7.3148 -3.2565 -7.3175 84.79
TUR GDSC1 -7.2902 -5.104 -7.2914 86.4609
BV-173 CTRP2 -7.287 -5.2509 -7.287 87.8816
KMS-12-BM GDSC1; CCLE -7.255 -5.8789 -7.255 87.5162
MLMA GDSC1 -7.2503 -4.8064 -7.2535 85.204
TF-1 CTRP2 -7.2427 -6.061 -7.2427 88.3782
KMOE-2 GDSC1 -7.229 -5.429 -7.2293 87.2966
EB1 CTRP2 -7.1876 -3.0395 -7.191 84.024
NKM-1 GDSC1 -7.1833 -5.305 -7.1837 86.6232
SUP-HD1 CTRP2 -7.1773 -3.7312 -7.178 85.1885
RPMI-8866 GDSC1 -7.1704 -4.8613 -7.1726 85.0181
ALL-SIL GDSC1; CCLE -7.1541 -5.8626 -7.1541 86.8208
Peer CTRP2 -7.1435 -6.3398 -7.1435 87.8428
RCH-ACV CTRP2 -7.089 -4.9996 -7.089 86.6722
MOLT-4 GDSC1 -7.0708 -5.7301 -7.0708 87.2299
RPMI-6666 GDSC1 -7.0689 -4.5028 -7.0742 83.2583
Kasumi-2 CCLE -7.0613 -4.5959 -7.0616 84.3059
MOLM-6 CTRP2 -7.0517 -5.3572 -7.0517 86.8356
CMK-86 CCLE -7.0366 -5.0991 -7.0367 85.0625
L-363 CTRP2 -7.0273 -4.3095 -7.0274 85.5244
SU-DHL-6 GDSC1; CCLE -7.0216 -5.973 -7.0216 85.9328
BV-173 GDSC1 -7.0088 -5.6483 -7.0088 86.5416
RS4;11 GDSC1 -7.006 -5.0435 -7.0067 84.7273
ATN-1 GDSC1 -7.0007 -6.1095 -7.0007 87.4872
HuNS1 CTRP2 -6.9893 -4.3595 -6.9894 85.4336
NU-DHL-1 CTRP2 -6.9814 -3.7721 -6.9818 84.5553
Loucy GDSC1 -6.9753 -5.8108 -6.9754 86.6688
697 GDSC1; CCLE -6.9557 -5.686 -6.9557 85.2415
MOLT-16 GDSC1; CCLE -6.948 -6.1948 -6.948 85.4149
Mono-Mac-1 CCLE -6.9458 -4.6755 -6.9459 83.8489
SU-DHL-4 CTRP2 -6.9436 -4.4102 -6.9436 85.3015
SU-DHL-8 CTRP2 -6.942 -4.6682 -6.942 85.6051
KOPN-8 GDSC1 -6.9356 -5.5669 -6.9356 85.7594
HH [Human lymphoma] GDSC1; CCLE -6.8957 -3.3022 -6.9034 80.8734
RS4;11 CTRP2 -6.8837 -4.7472 -6.8837 85.4093
NALM-6 GDSC1 -6.8776 -5.4951 -6.8776 85.1134
ALL-SIL CTRP2 -6.8594 -5.9369 -6.8594 85.9488
RL CTRP2 -6.8576 -4.9754 -6.8576 85.4878
EM-2 CTRP2 -6.8354 -5.8651 -6.8354 85.7837
WSU-DLCL2 CTRP2 -6.8173 -5.8426 -6.8173 85.6635
MOLP-8 GDSC1; CCLE -6.8138 -5.7381 -6.8138 84.1842
RPMI-8402 CTRP2 -6.8048 -5.7087 -6.8048 85.5599
SKM-1 GDSC1 -6.8004 -5.1842 -6.8005 83.718
CML-T1 CTRP2 -6.7865 -5.8152 -6.7865 85.4604
HuT 78 CCLE -6.7829 -4.5502 -6.783 82.7216
U266B1 CTRP2 -6.7822 -2.8559 -6.7849 82.3875
P31/FUJ CTRP2 -6.752 -5.6018 -6.752 85.2012
CTB-1 GDSC1 -6.7462 -3.5823 -6.7719 78.4949
OCI-AML-5 GDSC1; CCLE -6.7448 -5.1 -6.7448 83.201
RPMI-8226 GDSC1 -6.7375 -5.6125 -6.7375 84.0904
RPMI-8402 GDSC1; CCLE -6.7215 -5.6476 -6.7215 83.4093
DB GDSC1 -6.7007 -4.6761 -6.7019 81.5929
NALM-6 CTRP2 -6.6897 -5.2808 -6.6897 84.7155
KMS-27 CTRP2 -6.687 -5.8734 -6.687 84.8129
A3/Kawakami GDSC1 -6.6779 -5.9559 -6.6779 83.8204
JVM-3 CTRP2 -6.6721 -5.4686 -6.6721 84.6643
PF-382 GDSC1 -6.6644 -5.3317 -6.6645 82.8942
SUP-T1 CTRP2 -6.6584 -5.2308 -6.6584 84.5052
HL-60 GDSC1 -6.658 -5.6649 -6.658 83.3487
BC-1 GDSC1 -6.6539 -5.5319 -6.6539 83.1306
SIG-M5 GDSC1; CCLE -6.6495 -5.5474 -6.6495 82.7917
PF-382 CTRP2 -6.6423 -5.642 -6.6423 84.5022
BL-41 GDSC1; CCLE -6.6359 -5.5042 -6.6359 82.6663
NCO2 CTRP2 -6.635 -4.9596 -6.635 84.2387
BE-13 GDSC1 -6.6347 -5.6856 -6.6347 83.1189
SK-MM-2 GDSC1; CCLE -6.6275 -4.7181 -6.6276 81.9842
NOMO-1 CTRP2 -6.6052 -3.4131 -6.6057 82.5352
P12-Ichikawa GDSC1; CCLE -6.6012 -5.8067 -6.6012 82.4465
MOLM-16 CTRP2 -6.601 -5.7169 -6.601 84.2381
CESS GDSC1 -6.5966 -5.2448 -6.5966 82.0967
MOLP-2 CTRP2 -6.5847 -4.5927 -6.5847 83.7152
Jurkat GDSC1; CCLE -6.5683 -5.4581 -6.5683 82.1042
KMS-28BM CTRP2 -6.5576 11.97 -9.6833 63.8398
SU-DHL-10 GDSC1; CCLE -6.5549 -6.0544 -6.5549 82.0596
JVM-2 CTRP2 -6.5523 -0.854 -6.677 73.2717
OCI-AML-2 GDSC1; CCLE -6.5488 -5.4577 -6.5488 81.9449
NB4 CTRP2 -6.5358 -5.9059 -6.5358 83.8109
BALL-1 GDSC1 -6.5235 -5.3699 -6.5235 81.5636
RPMI-8226 CTRP2 -6.5232 -5.1721 -6.5232 83.6507
ME1 GDSC1 -6.5072 -1.2277 -6.8039 70.6137
KE-37 GDSC1 -6.5034 -5.8669 -6.5034 81.6969
WIL2 NS GDSC1 -6.5026 -4.714 -6.5031 80.1534
NCI-H929 CTRP2 -6.4929 -4.9016 -6.4929 83.3689
SUP-HD1 GDSC1 -6.4881 -4.7648 -6.4885 80.1442
SU-DHL-8 GDSC1; CCLE -6.4771 -5.1229 -6.4771 81.236
Mino CCLE -6.4617 -5.4994 -6.4617 81.2331
KHM-1B CTRP2 -6.4592 -5.3925 -6.4592 83.2824
JURL-MK1 CTRP2 -6.4575 -5.6796 -6.4575 83.2877
SKM-1 CTRP2 -6.4445 -5.9054 -6.4445 83.203
Ku812 CTRP2 -6.4363 -5.5833 -6.4363 83.1443
KYO-1 CTRP2 -6.4193 -5.3378 -6.4193 83.0166
MOLM-13 GDSC1 -6.4169 -5.0188 -6.4169 79.9705
Hs 445 GDSC1 -6.4154 -4.9648 -6.4155 79.8677
L-363 GDSC1; CCLE -6.4027 -4.6975 -6.4027 80.3913
HT CTRP2 -6.4022 -5.7145 -6.4022 82.9202
SU-DHL-5 GDSC1 -6.3977 -6.0225 -6.3977 80.3989
CCRF-CEM GDSC1 -6.3953 -5.2815 -6.3953 80.0897
THP-1 GDSC1 -6.3795 -5.0509 -6.3795 79.642
AML-193 CTRP2 -6.3713 -3.6844 -6.3714 81.7932
KM-H2 CTRP2 -6.3636 -4.4765 -6.3636 81.137
KMS-34 CCLE -6.361 -3.8766 -6.3616 79.186
EHEB CTRP2 -6.3366 -4.0257 -6.3366 81.931
KO52 CCLE -6.3305 -3.2911 -6.3337 78.1017
THP-1 CTRP2 -6.3027 -5.0086 -6.3027 82.2154
SU-DHL-10 CTRP2 -6.2951 -5.5771 -6.2951 82.2068
GA-10 GDSC1 -6.2808 -3.227 -6.3101 74.597
Ramos.2G6.4C10 GDSC1 -6.2793 -5.6592 -6.2793 78.9098
AMO1 CTRP2 -6.2569 -4.8139 -6.2569 81.8831
SUP-T1 GDSC1; CCLE -6.2549 -5.3581 -6.2549 79.4732
P32/ISH GDSC1 -6.2505 -4.2508 -6.2523 76.9616
L-1236 GDSC1 -6.238 -4.3306 -6.2392 77.0202
OCI-AML-2 CTRP2 -6.2241 -5.5925 -6.2241 81.7343
Hs 611.T CTRP2 -6.1716 -0.8579 -6.2023 77.0763
BL-70 CCLE -6.1685 -5.063 -6.1685 78.7093
HDLM-2 CTRP2 -6.1669 -2.0857 -6.1721 78.8939
MJ CCLE -6.1635 -3.0418 -6.168 76.7547
L-540 GDSC1 -6.1449 -4.4551 -6.1454 76.3812
KE-97 CTRP2 -6.1348 -3.4574 -6.1349 80.3811
Ku812 GDSC1; CCLE -6.134 -4.5087 -6.134 78.2347
HEL CTRP2 -6.1113 -4.7174 -6.1113 78.078
Jurkat CTRP2 -6.0982 -4.0039 -6.0982 77.6799
Karpas-620 GDSC1; CCLE -6.0836 -4.8883 -6.0836 77.9701
RPMI-6666 CTRP2 -6.0813 -4.1888 -6.0813 80.5854
OCI-AML-3 GDSC1 -6.077 -5.2532 -6.077 76.3603
Reh GDSC1; CCLE -6.0588 -4.6018 -6.0588 77.6847
Sc-1 GDSC1 -6.0558 -4.6357 -6.0559 75.7162
GDM-1 GDSC1 -6.0443 3.6942 -7.8634 60.8252
RL GDSC1 -6.0358 -3.0458 -6.0669 72.3826
Karpas-299 CTRP2 -6.0263 -4.662 -6.0263 80.3803
SCC-3 GDSC1 -6.0103 -4.1946 -6.0114 74.6369
OCI-Ly10 CCLE -6.0034 -2.5356 -6.0139 75.0369
DEL GDSC1; CCLE -5.9891 -4.1994 -5.9891 76.9364
Mono-Mac-6 GDSC1 -5.9576 -2.7078 -6.0082 70.9842
Reh CTRP2 -5.9227 -4.1547 -5.9227 79.6056
BC-3 GDSC1 -5.918 -4.9587 -5.918 74.3524
KCL-22 GDSC1; CCLE -5.9126 -4.1238 -5.9127 76.3038
SR GDSC1 -5.911 -1.7688 -6.0654 68.4699
DND-41 GDSC1 -5.905 -4.7574 -5.905 74.1156
IM-9 GDSC1 -5.8885 -3.7532 -5.8928 72.7067
PL21 CTRP2 -5.8873 -4.5755 -5.8873 79.4678
Karpas-299 GDSC1; CCLE -5.8836 -5.006 -5.8836 76.2907
Raji CTRP2 -5.8776 -3.1593 -5.8778 78.774
ROS-50 GDSC1 -5.8581 -4.2471 -5.8586 73.154
KE-97 CCLE -5.8547 -4.1569 -5.8547 75.8691
OCI-Ly19 GDSC1 -5.8449 -3.9467 -5.8468 72.6112
KMM-1 CCLE -5.8194 -3.7876 -5.8195 75.3777
HC-1 GDSC1 -5.8081 -4.0149 -5.8094 72.3365
HDLM-2 GDSC1 -5.802 -1.6634 -5.9648 67.5084
MHH-PREB-1 GDSC1 -5.7996 -1.8121 -5.9399 67.8104
L-540 CTRP2 -5.7831 -3.9495 -5.7832 78.6755
HAL-01 GDSC1 -5.7517 -3.9576 -5.7531 71.6762
SUP-T11 CTRP2 -5.7439 -1.3327 -5.7552 76.1241
HEL GDSC1 -5.7375 -4.5542 -5.7375 72.0402
ML-2 GDSC1 -5.7126 -3.7926 -5.715 71.0515
NOMO-1 GDSC1 -5.7103 -4.3733 -5.7104 71.623
Pfeiffer CCLE -5.7072 -3.6946 -5.7073 74.4673
HT GDSC1; CCLE -5.6799 -4.0617 -5.6799 74.433
TK [Human B-cell lymphoma] GDSC1 -5.6759 -3.8171 -5.6779 70.7059
KG-1 GDSC1; CCLE -5.6712 -4.5777 -5.6712 74.4597
CTV-1 GDSC1 -5.652 -4.8228 -5.652 71.0673
SU-DHL-4 GDSC1; CCLE -5.6346 -4.2721 -5.6346 74.1142
DND-41 CTRP2 -5.6327 2.6733 -5.9622 70.1905
K-562 CTRP2 -5.6045 -3.7199 -5.6045 77.4944
MEC-1 CCLE -5.602 -3.4158 -5.6024 73.4848
KHM-1B CCLE -5.5883 -3.1933 -5.5891 73.2107
F-36P CTRP2 -5.525 -2.7513 -5.5252 76.5441
U266B1 GDSC1 -5.478 -4.8165 -5.478 68.9013
JJN-3 GDSC1 -5.4679 -3.9195 -5.4685 68.5297
LAMA-84 GDSC1 -5.4387 -4.4975 -5.4387 68.3967
K-562 GDSC1 -5.4153 -3.881 -5.4159 67.8989
U-698-M GDSC1 -5.4034 -4.6192 -5.4034 67.9674
KCL-22 CTRP2 -5.3385 -2.9446 -5.3386 75.5793
L-428 CTRP2 -5.3214 -3.2007 -5.3214 75.5749
ME1 CTRP2 -5.3194 0.4955 -5.3907 71.9822
YT GDSC1 -5.3057 -3.6054 -5.3073 66.4526
Raji GDSC1; CCLE -5.2828 -2.7092 -5.2847 70.5877
JVM-3 GDSC1; CCLE -5.2242 -3.7851 -5.2242 70.6008
NCO2 CCLE -5.2125 -3.4903 -5.2125 70.4466
MEG-01 GDSC1; CCLE -5.1954 -3.6697 -5.1955 70.3429
SUP-M2 GDSC1; CCLE -5.1821 -3.3309 -5.1822 70.1522
KY821 GDSC1 -5.1589 -4.1771 -5.1589 64.903
DEL CTRP2 -5.1581 -3.4291 -5.1581 74.5911
Karpas-422 GDSC1; CCLE -5.1452 -3.466 -5.1452 69.8854
AMO1 GDSC1; CCLE -5.1309 -3.1411 -5.1312 69.6721
JURL-MK1 GDSC1 -5.0423 -4.0395 -5.0423 63.4468
U-937 CTRP2 -5.0243 -3.507 -5.0243 73.7261
LAMA-84 CTRP2 -5.0077 -2.8393 -5.0077 73.5125
JM-1 CCLE -4.951 -3.4247 -4.951 68.2554
L-428 GDSC1; CCLE -4.9261 -3.1839 -4.9262 68.009
GDM-1 CTRP2 -4.9063 -2.2581 -4.9065 72.6838
SU-DHL-1 CTRP2 -4.8552 -3.1077 -4.8552 72.5848
SR CTRP2 -4.8522 -1.1654 -4.8573 71.6878
KMS-18 CTRP2 -4.8081 -2.6867 -4.8081 72.215
EHEB GDSC1 -4.7237 -3.8516 -4.7237 59.472
EM-2 GDSC1; CCLE -4.717 -1.9536 -4.7224 65.8328
VAL GDSC1 -4.6856 -1.6939 -4.7681 58.0557
EB2 GDSC1; CCLE -4.6493 -3.5074 -4.6493 65.6919
U-937 CCLE -4.6397 -2.5611 -4.6403 65.4966
Farage GDSC1 -4.613 -3.8015 -4.613 58.0893
P31/FUJ GDSC1; CCLE -4.5589 -3.8892 -4.5589 64.9175
RC-K8 GDSC1 -4.5491 -2.3811 -4.5678 57.0283
Ci-1 CCLE -4.5348 -3.0223 -4.5349 64.6958
DG-75 GDSC1 -4.4834 0.9169 -5.1624 54.3366
WSU-NHL GDSC1 -4.4686 -3.9038 -4.4686 56.2852
OCI-M1 GDSC1 -4.4294 -3.2799 -4.4296 55.7893
Jiyoye GDSC1 -4.389 -2.6239 -4.3955 55.2143
MC116 GDSC1; CCLE -4.3813 -4.0943 -4.3813 63.3925
ARH-77 GDSC1 -4.268 -3.3778 -4.2681 53.7777
Ci-1 CTRP2 -4.1733 -3.1502 -4.1733 68.0715
GR-ST GDSC1 -4.0726 1.7446 -5.0084 50.8525
HD-MY-Z CTRP2 -4.0017 -0.3946 -4.0089 66.4336
Granta-519 GDSC1; CCLE -3.9867 -2.0289 -3.9874 59.9651
Toledo CCLE -3.9651 -1.7633 -3.967 59.7454
HEL 92.1.7 CCLE -3.9337 -3.1737 -3.9337 59.5485
SU-DHL-1 GDSC1 -3.9009 -3.0465 -3.901 49.1894
DoHH2 GDSC1; CCLE -3.8644 -0.7437 -3.8868 58.6351
MN-60 GDSC1 -3.8636 2.5416 -5.0942 49.2396
P3HR-1 CCLE -3.8278 -1.6006 -3.8302 58.5737
HD-MY-Z CCLE -3.7103 -1.8433 -3.711 57.6105
BDCM CCLE -3.4524 -1.5338 -3.4535 55.3996
PL-21 GDSC1 -3.3503 3.1639 -4.8145 45.4868
KMS-11 GDSC1; CCLE -3.2734 -1.0801 -3.2771 53.8539
Daudi GDSC1 -3.266 -0.3509 -3.47 42.1034
L-1236 CTRP2 -3.1391 8.813 -4.8503 56.6514
LP-1 GDSC1; CCLE -2.9463 3.6348 -3.6732 50.8007
KM-H2 GDSC1 -2.9306 -0.0055 -3.1906 38.3896
MHH-CALL-3 CTRP2 -2.8145 58.8325 -28.0528 51.199
EJM GDSC1 -2.8015 11.7424 -8.3236 45.7418
EB1 CCLE -2.4514 1.1455 -2.5645 46.9955
EoL-1 GDSC1 -1.6903 2.6212 -2.8767 29.0938
VL51 GDSC1 -1.6792 -0.3056 -1.7551 21.9057
WSU-DLCL2 GDSC1 -0.616 11.3718 -6.1851 35.6956
Mono-Mac-6 CTRP2 0.2524 54.366 -23.0982 48.2751
JVM-2 GDSC1 2.0179 4.6046 -0.8862 2.5002
P3HR-1 CTRP2 2.084 20.2213 -4.5652 40.0723
KMM-1 CTRP2 6.1423 19.3858 -0.5449 24.3608
MC116 CTRP2 6.3526 10.2572 4.189 7.222
REC-1 CTRP2 6.6322 13.4355 2.8266 12.2995
Karpas-620 CTRP2 7.0625 9.7048 4.9772 2.8592
⏷ Show the Full List of 324 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 48 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 -5.7657 -2.2407 -5.7677 77.324
TE15 CTRP2 -5.298 -1.5681 -5.3022 74.3451
OE33 CTRP2 -7.2582 -2.7677 -7.2643 83.7396
TE-4 GDSC1 -5.7733 -4.7908 -5.7733 72.5529
TE-1 CTRP2 -5.556 -2.5386 -5.5566 76.5519
TE-5 CTRP2 -5.4837 0.4067 -5.5555 72.7338
OE19 GDSC1 -5.3414 -4.4239 -5.3414 67.1853
TE-10 GDSC1 -5.2142 -2.7691 -5.2339 64.6021
OE21 GDSC1; CCLE -5.0275 -3.5728 -5.0275 68.9182
TE-1 GDSC1; CCLE -4.9269 -1.9457 -4.9348 67.3825
OE21 CTRP2 -4.9018 -0.9897 -4.9094 71.7983
KYSE-410 GDSC1; CCLE -4.8511 -3.1882 -4.8512 67.3841
KYSE-70 GDSC1; CCLE -4.7859 -3.0817 -4.7859 66.8212
OE19 CTRP2 -4.5919 -1.3428 -4.5941 70.3693
TE-6 CTRP2 -4.5366 -1.751 -4.5372 70.241
COLO 680N GDSC1 -4.1535 -1.9375 -4.1848 52.2589
T.T GDSC1 -4.142 -2.2854 -4.154 52.1638
OE33 GDSC1; CCLE -4.0071 -2.1031 -4.0077 60.1458
KYSE-150 GDSC1; CCLE -3.9001 -2.174 -3.9004 59.2447
KYSE-450 GDSC1; CCLE -3.8806 -1.6367 -3.883 59.02
KYSE-520 GDSC1; CCLE -3.7306 2.1532 -4.1326 56.1886
EC-GI-10 CTRP2 -3.6967 0.3351 -3.7148 64.2836
TE-14 CTRP2 -3.6807 -0.5107 -3.6841 64.5582
KYSE-70 CTRP2 -3.6494 -0.1988 -3.656 64.2549
EC-GI-10 GDSC1 -3.5406 -1.349 -3.5945 44.8797
TE-9 GDSC1; CCLE -3.5148 -1.3092 -3.5178 55.9114
TE-4 CTRP2 -3.5025 -0.1471 -3.5084 63.3419
KYSE-410 CTRP2 -3.2524 -0.5356 -3.2537 61.8603
COLO 680N CTRP2 -3.1953 -0.3766 -3.1972 61.4678
TE-10 CTRP2 -3.1704 -0.279 -3.1728 61.2917
KYSE-180 GDSC1; CCLE -3.1099 -0.8598 -3.1151 52.4562
TE-15 GDSC1; CCLE -3.093 0.0361 -3.132 52.2511
KYSE-140 GDSC1; CCLE -3.0518 0.4102 -3.118 51.8779
KYSE-30 CCLE -2.8979 -0.2908 -2.9142 50.6425
TE-9 CTRP2 -2.8261 -0.482 -2.8266 59.0758
KYSE-510 GDSC1; CCLE -2.5433 -0.798 -2.5448 47.6107
KYSE-180 CTRP2 -2.506 0.9109 -2.5187 56.8448
TE-11 CTRP2 -2.208 1.3716 -2.2284 54.8766
TE-5 GDSC1; CCLE -1.7635 1.6803 -1.9068 41.3733
KYSE-150 CTRP2 -1.3965 1.5124 -1.406 49.5752
KYSE-140 CTRP2 -1.3842 4.6853 -1.7361 49.5536
TE-8 GDSC1 -1.1675 41.6477 -21.7822 46.4285
TE-11 GDSC1; CCLE -1.1003 1.3406 -1.1543 35.4382
KYSE-270 GDSC1 -1.0102 10.6684 -6.1765 37.0102
KYSE-450 CTRP2 -1.0081 3.5486 -1.142 47.1433
KYSE-510 CTRP2 -0.9612 2.5658 -1.0016 46.735
KYSE-30 CTRP2 -0.8655 4.3096 -1.1037 46.3525
KYSE-520 CTRP2 -0.7476 10.3683 -2.8737 47.0089
⏷ Show the Full List of 48 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 74 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 -1.8044 5.4731 -2.3722 51.8589
MIA PaCa-2 CTRP2 -5.9618 -4.1442 -5.9618 79.843
AsPC-1 GDSC1; CCLE -5.1801 -2.121 -5.1879 69.3315
PaTu 8988s CTRP2 -5.1293 5.6587 -6.0467 65.3104
MZ-PC-1 GDSC1 -4.7849 1.1113 -5.5542 56.4447
HuP-T4 GDSC1; CCLE -4.5308 -2.5383 -4.5313 64.5952
Panc 02.03 GDSC1; CCLE -4.4162 -2.0852 -4.4181 63.5325
QGP-1 GDSC1; CCLE -4.2382 1.11 -4.4751 60.0371
BxPC-3 CTRP2 -4.1818 -1.4132 -4.1825 67.9445
DAN-G CTRP2 -4.166 -1.4733 -4.1666 67.8643
Panc 03.27 GDSC1; CCLE -4.141 -2.0069 -4.1423 61.2537
Panc 10.05 GDSC1; CCLE -4.0823 -1.0868 -4.0973 60.4834
L3.3 CCLE -3.9535 -1.8909 -3.9546 59.6688
PL4 GDSC1 -3.9247 -1.7432 -3.9609 49.5044
KCI-MOH1 CCLE -3.8956 -2.1021 -3.8959 59.2014
Panc 04.03 CTRP2 -3.8658 -0.3238 -3.8727 65.6017
SUIT-2 GDSC1; CCLE -3.8132 -0.6514 -3.8382 58.1978
DAN-G GDSC1 -3.7987 -2.6214 -3.7995 47.9137
AsPC-1 CTRP2 -3.7565 1.0214 -3.8039 64.1904
MIA PaCa-2 GDSC1; CCLE -3.7323 -2.2319 -3.7324 57.8144
HuP-T4 CTRP2 -3.7283 0.326 -3.7467 64.4692
Capan-1 GDSC1 -3.6592 -1.9499 -3.6726 46.2133
PK-45H CTRP2 -3.6486 1.7103 -3.7386 63.1385
PSN1 GDSC1; CCLE -3.6399 -1.6914 -3.6409 57.0019
BxPC-3 GDSC1; CCLE -3.6002 -1.5234 -3.6019 56.6523
PK-45H CCLE -3.5373 -1.5821 -3.5385 56.1245
PaTu 8902 GDSC1; CCLE -3.5335 -1.9355 -3.5337 56.1063
CFPAC-1 GDSC1 -3.5069 -1.9353 -3.517 44.3098
PL45 CCLE -3.4856 -1.1955 -3.4897 55.6544
SU.86.86 GDSC1; CCLE -3.3946 -2.3219 -3.3946 54.9178
KP-4 GDSC1; CCLE -3.2797 -1.5489 -3.2802 53.9261
HuP-T3 GDSC1; CCLE -3.2627 -0.6349 -3.2754 53.7265
SU.86.86 CTRP2 -3.246 -1.1241 -3.2461 61.8771
Panc 08.13 CTRP2 -3.2214 -0.4648 -3.223 61.65
PK-1 CCLE -3.2112 -0.1597 -3.2425 53.242
KP-2 CCLE -3.203 -0.942 -3.208 53.2497
PK-59 CTRP2 -3.1352 0.1115 -3.1411 60.9871
QGP-1 CTRP2 -3.1155 3.692 -3.4221 59.1624
KP-3 GDSC1; CCLE -3.0731 -0.6105 -3.083 52.1333
HPAC GDSC1; CCLE -3.0361 -0.3534 -3.0533 51.8079
Hs 766T GDSC1; CCLE -3.0262 -0.3797 -3.0422 51.7262
PaTu 8902 CTRP2 -3.0245 0.0438 -3.0287 60.301
PSN1 CTRP2 -2.9861 2.0024 -3.0696 59.3945
Panc 08.13 GDSC1 -2.9503 0.5396 -3.3737 39.3013
Panc 05.04 CTRP2 -2.9238 -0.3052 -2.9251 59.7023
YAPC GDSC1 -2.9224 0.6834 -3.3904 39.1627
TCC-Pan2 CTRP2 -2.9063 -1.1431 -2.9063 59.6281
PK-59 CCLE -2.9056 -1.6148 -2.9056 50.7181
Hs 766T CTRP2 -2.9039 1.3945 -2.9439 59.1737
SW1990 CTRP2 -2.8031 2.354 -2.909 58.207
KP-3 CTRP2 -2.778 0.1092 -2.7812 58.7083
SW1990 GDSC1; CCLE -2.643 1.0555 -2.7569 48.5574
Panc 10.05 CTRP2 -2.6088 0.6181 -2.6169 57.5479
Capan-2 GDSC1; CCLE -2.4592 1.7039 -2.6606 47.1622
KP-4 CTRP2 -2.4473 -0.2175 -2.4477 56.5633
CFPAC-1 CTRP2 -2.428 -0.8624 -2.428 56.4437
KP-1N GDSC1; CCLE -2.355 2.2051 -2.6478 46.4505
SNU-213 CTRP2 -2.3531 -0.7093 -2.3532 55.9449
L3.3 CTRP2 -2.3336 0.6287 -2.339 55.7683
Panc 04.03 GDSC1; CCLE -2.3325 -0.2978 -2.3383 45.8126
HuP-T3 CTRP2 -2.1304 3.6298 -2.3526 53.975
KP-2 CTRP2 -2.0874 2.3155 -2.1555 53.9794
HPAF-II GDSC1; CCLE -2.0542 2.1065 -2.3 44.003
Panc 03.27 CTRP2 -2.0109 0.7517 -2.015 53.646
PaTu 8988t GDSC1 -1.7682 0.4861 -2.0725 24.5422
KP-1NL CCLE -1.7499 1.7027 -1.8958 41.2674
Panc 02.03 CTRP2 -1.3578 3.8912 -1.5642 49.3716
HPAC CTRP2 -1.2253 1.3126 -1.2295 48.4364
PaTu 8988t CTRP2 -0.9611 2.632 -1.0056 46.7394
HPAF-II CTRP2 -0.8547 2.6753 -0.898 46.0397
SUIT-2 CTRP2 -0.5881 4.0422 -0.7619 44.5164
YAPC CTRP2 -0.2528 4.5503 -0.4852 42.4794
Capan-2 CTRP2 0.4586 6.7257 -0.2503 39.0357
SNU-410 CTRP2 4.1279 37.0901 -11.1031 40.9741
⏷ Show the Full List of 74 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 117 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 -4.5269 2.8176 -4.7984 66.1151
IGR-1 CTRP2 -5.9305 -2.6133 -5.9316 78.5182
A-431 GDSC1 -5.8418 -3.7972 -5.8451 72.3408
IGR-1 GDSC1 -5.5568 -0.9055 -5.839 64.3542
CHL-1 GDSC1; CCLE -5.5413 -1.3369 -5.5848 70.579
RPMI-7951 CTRP2 -5.3444 -2.6426 -5.3446 75.4547
Mel Ho CTRP2 -5.3123 -3.0547 -5.3123 75.4671
MeWo CTRP2 -5.301 -0.585 -5.3226 73.274
G-361 GDSC1; CCLE -5.2373 -2.2875 -5.2431 69.8916
G-361 CTRP2 -5.231 -1.7347 -5.2337 74.1589
COLO 800 GDSC1 -5.211 -0.5398 -5.5441 61.3002
SK-MEL-2 GDSC1; CCLE -5.1871 -3.8708 -5.1871 70.2964
Hs 936.T CCLE -5.1697 -2.5343 -5.1723 69.6206
Hs 938.T GDSC1; CCLE -5.1348 -2.6143 -5.1367 69.4196
MZ-MEL-7 GDSC1 -5.1341 -3.0497 -5.1422 64.0704
WM88 CTRP2 -5.1131 -0.5023 -5.1336 72.3328
Malme-3M CTRP2 -5.1016 7.2826 -6.4789 63.8039
Hs 294T CTRP2 -5.0619 -3.028 -5.0619 73.9013
COLO 679 GDSC1; CCLE -5.0618 -1.0653 -5.1046 67.3807
Mel Ho GDSC1; CCLE -5.0537 -3.5523 -5.0537 69.1364
LOX-IMVI CTRP2 -5.0264 -2.9163 -5.0264 73.6504
HT-144 GDSC1; CCLE -4.9284 -2.04 -4.9347 67.4683
SK-MEL-5 GDSC1; CCLE -4.9052 -2.6262 -4.9062 67.6566
M14 GDSC1 -4.8491 -1.6358 -4.9493 59.6283
Mel JuSo GDSC1 -4.8464 -2.3483 -4.8771 60.3148
UACC-257 GDSC1; CCLE -4.826 -2.4485 -4.8276 66.9493
SK-MEL-3 GDSC1 -4.8098 -2.3006 -4.8422 59.8811
WM266-4 CCLE -4.7743 -2.7888 -4.7746 66.6624
K029AX CTRP2 -4.7735 -1.2968 -4.7769 71.3618
MeWo GDSC1; CCLE -4.7692 -2.2779 -4.7716 66.4198
MMAc-SF GDSC1 -4.7103 -2.4146 -4.7324 58.8785
LB373-MEL-D GDSC1 -4.6623 -1.9683 -4.7144 58.0327
Malme-3M CCLE -4.6401 -0.6384 -4.6942 64.2027
LB2518-MEL GDSC1 -4.6101 -1.8283 -4.6732 57.3734
Hs 695T CCLE -4.57 -1.4722 -4.5831 64.414
RPMI-7951 GDSC1; CCLE -4.5565 -2.8894 -4.5565 64.8671
WM278 GDSC1 -4.509 -3.1519 -4.5098 56.767
K029AX CCLE -4.4917 -1.7989 -4.4971 64.0138
WM266-4 CTRP2 -4.4447 -1.4621 -4.4459 69.5658
COLO 800 CTRP2 -4.4435 -0.2587 -4.4589 68.7943
COLO 783 GDSC1 -4.4213 -1.2802 -4.5427 55.0309
Hs 936.T CTRP2 -4.4155 -1.0494 -4.4188 69.1858
HMCB CCLE -4.3957 -1.8335 -4.3998 63.2744
UACC-257 CTRP2 -4.3827 0.287 -4.4139 68.0206
CP66-MEL GDSC1 -4.3351 -2.1702 -4.3582 54.4563
GAK GDSC1 -4.2949 -3.2913 -4.295 54.1131
MZ-MEL-2 GDSC1 -4.2663 -2.1551 -4.288 53.6398
WM115 GDSC1; CCLE -4.256 -3.3377 -4.256 62.3163
IGR-37 GDSC1; CCLE -4.1781 -1.5681 -4.1838 61.4368
SK-MEL-2 CTRP2 -4.1467 -1.9113 -4.1468 67.8357
SK-MEL-3 CTRP2 -4.1397 -0.8687 -4.1429 67.4785
UACC-62 CTRP2 -4.1316 -2.2623 -4.1316 67.7746
SK-MEL-30 GDSC1; CCLE -4.1135 0.6772 -4.2744 59.5871
COLO 829 GDSC1 -4.09 1.931 -5.0969 50.9671
A101D GDSC1 -4.0812 -2.4048 -4.0882 51.4281
IGR-37 CTRP2 -4.0784 -2.5767 -4.0784 67.4358
LOX-IMVI GDSC1; CCLE -4.0324 -2.7014 -4.0324 60.393
MDA-MB-435S CCLE -4.0259 -2.0077 -4.0268 60.2925
IPC-298 GDSC1; CCLE -4.0152 -1.1256 -4.0278 59.9727
Hs 852.T CTRP2 -3.9437 7.215 -5.1966 60.2722
WM793 GDSC1; CCLE -3.9344 -2.342 -3.9345 59.5449
IST-MEL1 GDSC1 -3.8969 -2.5707 -3.8987 49.1418
Hs 895.T CTRP2 -3.8681 1.8942 -3.9852 64.0952
Hs 944.T CCLE -3.8668 -1.7933 -3.8681 58.9281
Hs 294T CCLE -3.8469 -2.3153 -3.847 58.7972
Hs 852.T CCLE -3.8312 -1.584 -3.8338 58.5999
A101D CTRP2 -3.8149 -2.1866 -3.8149 65.6791
WM983B CTRP2 -3.7808 5.33 -4.4919 60.9702
A-375 GDSC1; CCLE -3.7683 -1.4037 -3.7723 58.0457
CP50-MEL-B GDSC1 -3.7677 -0.4353 -3.9968 47.8549
SK-MEL-31 CCLE -3.7594 -2.5225 -3.7594 58.0503
SK-MEL-28 GDSC1 -3.7365 -1.2842 -3.8101 47.2893
COLO 792 CTRP2 -3.7262 0.5869 -3.753 64.3064
451Lu GDSC1 -3.7208 -0.6457 -3.9001 47.2712
COLO 829 CTRP2 -3.6943 1.0205 -3.7397 63.8567
A2058 CTRP2 -3.6747 -1.5702 -3.6748 64.725
SK-MEL-24 GDSC1; CCLE -3.665 -1.9819 -3.6653 57.232
SK-MEL-5 CTRP2 -3.6492 -1.127 -3.6497 64.5075
Hs 895.T CCLE -3.5636 0.9861 -3.7307 55.6346
WM88 CCLE -3.3225 -1.1964 -3.3253 54.2772
SH-4 GDSC1 -3.2443 2.8365 -4.5653 44.4413
SK-MEL-1 CTRP2 -3.2321 -2.4805 -3.2321 61.8016
WM983B CCLE -3.2061 2.4306 -3.6263 52.6793
Hs 944.T CTRP2 -3.1778 -0.0425 -3.1822 61.2911
UACC-62 GDSC1; CCLE -3.1182 -1.8868 -3.1182 52.5441
IGR-39 CCLE -3.0585 0.554 -3.139 51.9167
COLO 741 CCLE -3.0528 -0.4213 -3.068 51.9519
HT-144 CTRP2 -3.0495 0.8353 -3.0701 60.246
HMV-II GDSC1 -2.9319 -0.3685 -3.1024 37.9873
WM115 CTRP2 -2.9194 -0.7557 -2.9196 59.7045
IPC-298 CTRP2 -2.8421 1.5679 -2.8895 58.7437
A-375 CTRP2 -2.8056 -0.7505 -2.8058 58.9519
SF8657 CCLE -2.7447 0.686 -2.8215 49.3675
RVH-421 GDSC1; CCLE -2.5441 0.5245 -2.5959 47.6872
A2058 GDSC1; CCLE -2.5319 -0.0007 -2.5507 47.5413
RVH-421 CTRP2 -2.5254 0.1138 -2.5273 57.0618
DJM-1 GDSC1 -2.4325 1.5807 -3.1952 35.0169
A-388 GDSC1 -2.4315 -0.6052 -2.513 31.3297
Mel JuSo CTRP2 -2.3235 0.5359 -2.3277 55.7099
HMCB CTRP2 -2.1624 2.3684 -2.2381 54.4313
WM1799 CCLE -2.0092 1.0716 -2.0858 43.2479
IGR-39 CTRP2 -1.8835 9.7834 -3.8541 51.7138
COLO 741 CTRP2 -1.7869 13.1211 -5.1044 51.0924
MDA-MB-435S CTRP2 -1.7272 1.4806 -1.7413 51.7545
SK-MEL-1 GDSC1 -1.5707 9.5386 -6.1138 38.9161
SK-MEL-31 CTRP2 -1.562 1.0018 -1.5654 50.6727
G-mel GDSC1 -1.4892 5.1904 -3.9022 32.7763
WM1799 CTRP2 -1.4281 3.0356 -1.5283 49.7934
SK-MEL-30 CTRP2 -1.1632 2.3677 -1.1991 48.0554
CJM [Human melanoma] CTRP2 -1.0359 1.8277 -1.0473 47.1884
WM793 CTRP2 -0.9662 1.1667 -0.9676 46.7087
WT2-iPS GDSC1; CCLE -0.7736 4.1882 -1.4945 35.165
WM1552C GDSC1 -0.3813 8.6575 -4.6284 30.7518
SK-MEL-28 CTRP2 0.6288 1.7129 0.6288 36.0795
WT2-iPS CTRP2 2.0081 12.4461 -0.9275 35.1612
Hs 839.T CTRP2 3.8062 7.9622 2.9024 18.2633
Hs 688(A).T CTRP2 6.3741 15.0912 1.7927 16.6975
⏷ Show the Full List of 117 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ESO-26 GDSC1 -5.6021 -4.7446 -5.6021 70.4425
KYAE-1 GDSC1 -4.9954 -3.8206 -4.9954 62.8444
FLO-1 GDSC1 -4.9782 -3.3656 -4.9798 62.5101
OACP4 C GDSC1 -4.5205 -2.3902 -4.538 56.7019
KYSE-220 GDSC1 -4.3511 -2.5087 -4.3601 54.733
SK-GT-4 GDSC1 -4.0469 -1.8735 -4.0783 50.9787
HCE-4 GDSC1 -3.8834 -1.9998 -3.901 48.9899
KYSE-50 GDSC1 -1.5266 0.7837 -1.9197 22.1668
OACM5.1 C GDSC1 -1.2554 2.1074 -2.2061 22.7336
TE-12 GDSC1 0.9074 8.8765 -3.682 22.5298
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1 -4.893 0.715 -5.5432 57.5412
COLO 684 CTRP2 -4.0591 4.5258 -4.6074 62.6776
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IMR-32 CTRP2 -9.2568 -5.0919 -9.2579 92.1828
SK-N-DZ CTRP2 -8.2098 -6.9122 -8.2098 93.9983
NH-6 CTRP2 -8.0187 -4.0952 -8.0201 88.1903
NB69 GDSC1 -7.9608 -5.7462 -7.9616 91.2404
CHP-134 GDSC1 -7.511 -4.3339 -7.5265 84.5042
NB1 GDSC1 -7.4535 -4.8146 -7.4582 86.0828
SJNB-14 GDSC1 -7.4252 -5.1837 -7.4266 87.3487
KP-N-YS GDSC1 -7.3807 -5.3548 -7.3813 87.7875
CHP-212 GDSC1; CCLE -7.3618 -3.7429 -7.3679 83.6711
TGW GDSC1 -7.231 -4.9429 -7.2329 85.6032
MHH-NB-11 GDSC1 -6.8311 -3.8196 -6.8493 79.7193
MHH-NB-11 CTRP2 -6.7194 -3.4748 -6.7199 83.0923
GOTO GDSC1 -6.7142 0.7309 -7.532 67.5196
NB(TU)1 GDSC1 -6.6624 -4.1236 -6.6694 79.7014
CHP-126 CTRP2 -6.6457 -4.922 -6.6457 84.2788
IMR-5 GDSC1 -6.6099 -5.3237 -6.6099 82.3633
NH-12 GDSC1 -6.5106 -3.7127 -6.5254 77.4969
Kelly CTRP2 -6.2603 -4.6301 -6.2603 81.8485
LA-N-6 GDSC1 -6.2238 -1.8752 -6.3847 70.6687
SK-N-MC-IXC GDSC1 -6.1509 -5.0819 -6.1509 77.1696
SK-N-FI CTRP2 -6.1273 -4.1867 -6.1273 80.8577
SJNB-6 GDSC1 -6.1075 -4.6725 -6.1076 76.3107
SiMa GDSC1; CCLE -6.1044 -3.5009 -6.1055 77.0666
SiMa CTRP2 -5.9808 -4.1262 -5.9808 79.9523
Kelly GDSC1; CCLE -5.8818 -4.8005 -5.8818 76.2638
SJNB-10 GDSC1 -5.7047 -3.7748 -5.7073 70.9461
SJNB-13 GDSC1 -5.6765 -4.7307 -5.6765 71.3574
SK-N-BE(2)-M17 GDSC1 -5.667 -4.151 -5.6673 70.9641
NB1 CTRP2 -5.6152 -3.9757 -5.6152 77.6224
SK-N-BE(2) CCLE -5.5524 -3.6334 -5.5525 73.2357
SJNB-5 GDSC1 -5.431 -3.9968 -5.4313 68.151
SK-N-DZ GDSC1; CCLE -5.4053 -3.276 -5.4056 71.8985
SK-N-AS GDSC1; CCLE -5.3835 -1.1334 -5.4336 69.3912
SJNB-12 GDSC1 -5.3606 4.9346 -7.6568 56.9777
KP-N-YN GDSC1 -5.2891 -0.4692 -5.646 61.7703
SK-N-SH GDSC1; CCLE -5.1383 -2.3024 -5.143 69.204
KP-N-SI9s CTRP2 -5.1328 -2.5915 -5.1329 74.1891
GI-ME-N GDSC1 -5.0852 -0.2412 -5.48 59.9679
KP-N-SI9s CCLE -4.9917 -2.5115 -4.9936 68.2684
SK-N-FI GDSC1; CCLE -4.9048 -2.3438 -4.9075 67.5028
SK-N-SH CTRP2 -4.6617 -0.007 -4.6886 69.6766
SJNB-7 GDSC1 -4.6522 1.0189 -5.3793 55.5558
IMR-32 CCLE -4.6321 -3.7526 -4.6321 65.546
SK-N-BE(2) CTRP2 -4.3376 1.0448 -4.4073 67.1027
SJNB-17 GDSC1 0.1719 9.2465 -4.4577 28.1931
KP-N-YN CTRP2 5.6711 7.227 5.1191 4.6754
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-1079 CTRP2 -7.4668 -4.0648 -7.4673 86.6943
SNU-245 CTRP2 -5.5685 0.163 -5.6286 73.3886
SNU-869 CTRP2 -4.9847 0.6853 -5.0556 70.3841
SNU-478 CTRP2 -4.5913 -2.1744 -4.5914 70.7208
HuCC-T1 GDSC1; CCLE -4.1454 -1.1666 -4.1593 61.0117
HuH-28 CTRP2 -4.0965 -0.7004 -4.1009 67.143
SNU-1196 CTRP2 -3.3959 -0.7459 -3.3968 62.8167
SNU-308 CTRP2 -2.7228 0.5883 -2.7317 58.2798
HuCC-T1 CTRP2 7.8255 9.3555 5.5353 0.3461
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 123 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU4475 CTRP2 -8.8775 6.7594 -10.441 72.3352
MDA-MB-453 CTRP2 -7.7422 -5.1945 -7.7422 89.541
HCC1428 CTRP2 -7.6039 -5.7806 -7.6039 89.9479
DU4475 GDSC1 -7.5833 -6.1919 -7.5833 91.7669
EFM-192A CTRP2 -7.4526 -5.0608 -7.4527 88.3064
Hs 578T CTRP2 -7.3309 -3.432 -7.3328 85.1538
HCC1599 GDSC1 -7.0532 -5.9247 -7.0532 87.5893
MDA-MB-453 GDSC1; CCLE -7.0167 -5.6401 -7.0167 85.639
CAL-148 CTRP2 -6.6423 -5.7405 -6.6423 84.5108
BT-474 GDSC1; CCLE -6.3153 -4.5521 -6.3154 79.6337
HCC1428 GDSC1 -6.3075 -4.9141 -6.3075 78.7119
HCC2218 CTRP2 -6.2394 -2.1083 -6.2448 79.2152
MDA-MB-330 GDSC1 -6.1992 0.4136 -6.8758 65.7505
HCC2218 GDSC1 -6.1628 -3.9921 -6.1665 75.64
EFM-19 GDSC1; CCLE -6.1418 -3.8805 -6.1421 77.7681
HCC1419 CTRP2 -6.1081 -3.9188 -6.1081 80.5947
AU565 GDSC1; CCLE -6.0152 -4.5137 -6.0152 77.3006
HCC1419 GDSC1 -5.9535 -2.9465 -5.9875 71.5213
CAL-148 GDSC1 -5.9461 -4.4715 -5.9463 74.3509
HCC1500 CTRP2 -5.9375 -1.2622 -5.9527 76.8158
HCC2157 GDSC1 -5.8259 -2.7424 -5.8684 70.0645
HCC202 GDSC1 -5.8112 -2.2934 -5.8923 68.9503
CAMA-1 GDSC1; CCLE -5.6998 -3.7945 -5.6999 74.4705
T-47D GDSC1; CCLE -5.6688 -2.4086 -5.6774 72.8767
OCUB-M GDSC1 -5.6618 -3.5646 -5.6667 70.2083
HCC1500 GDSC1 -5.6437 -4.5595 -5.6437 70.9181
AU565 CTRP2 -5.5288 -2.8819 -5.5289 76.6528
MDA-MB-361 GDSC1 -5.5188 -2.3759 -5.5766 66.8069
MCF-7 CTRP2 -5.4338 9.0307 -7.4084 63.3443
COLO 824 GDSC1 -5.4332 -3.9569 -5.4336 68.1542
MCF-7 GDSC1 -5.2942 -1.2827 -5.4815 63.0541
UACC-893 GDSC1 -5.1827 -3.31 -5.1864 64.8354
HCC1187 GDSC1; CCLE -5.1664 -2.8908 -5.1672 69.8339
MDA-MB-361 CTRP2 -5.1032 -1.1739 -5.1102 72.9899
SK-BR-3 CCLE -4.968 -3.0565 -4.9682 68.3235
ZR-75-30 GDSC1; CCLE -4.9242 -2.3356 -4.9271 67.6457
MRK-nu-1 GDSC1 -4.8707 -2.6347 -4.887 60.8205
ZR-75-30 CTRP2 -4.7761 5.1614 -5.5355 64.6712
HCC1569 GDSC1; CCLE -4.7444 -2.4259 -4.7458 66.2943
HCC1806 GDSC1; CCLE -4.5821 -2.5523 -4.5826 65.0217
HCC202 CTRP2 -4.5284 0.2125 -4.5603 68.8143
BT-474 CTRP2 -4.5145 -2.1115 -4.5146 70.2218
T-47D CTRP2 -4.3222 -2.5931 -4.3223 69.0498
ZR-75-1 CCLE -4.3108 -3.5613 -4.3108 62.7871
CAL-85-1 CTRP2 -4.2593 5.0513 -4.9455 62.9864
BT-483 GDSC1 -4.2184 6.4033 -7.1392 51.2363
HCC38 GDSC1 -4.2162 -2.4405 -4.2246 53.0854
CAL-51 CTRP2 -4.1933 -0.7893 -4.1975 67.7553
MFM-223 GDSC1 -4.1762 -2.8424 -4.1774 52.6234
HCC70 GDSC1; CCLE -4.1246 -2.2202 -4.1251 61.1495
HCC1143 CTRP2 -4.0213 0.0018 -4.0363 66.316
MDA-MB-157 GDSC1; CCLE -3.9781 -2.5774 -3.9781 59.9255
CAMA-1 CTRP2 -3.9181 8.8842 -5.7173 59.2006
HCC1569 CTRP2 -3.9152 -1.7137 -3.9153 66.3093
HCC1954 CTRP2 -3.8861 -0.1355 -3.8962 65.6262
Hs 578T GDSC1; CCLE -3.8846 -0.9581 -3.8997 58.8746
MDA-MB-468 GDSC1; CCLE -3.7326 -1.8142 -3.7333 57.797
MDA-MB-157 CTRP2 -3.5364 -0.3856 -3.54 63.6266
CAL-120 CTRP2 -3.4901 -0.9987 -3.4906 63.4617
HCC38 CTRP2 -3.3869 2.6799 -3.5626 61.1369
MDA-MB-231 CTRP2 -3.3018 -0.7938 -3.3025 62.2151
HCC1954 GDSC1; CCLE -3.2934 0.7013 -3.404 53.7291
BT-20 GDSC1; CCLE -3.2442 0.1457 -3.2972 53.462
YMB-1-E GDSC1 -2.9094 2.0891 -3.904 40.7609
UACC-812 GDSC1; CCLE -2.8077 -0.623 -2.8134 49.8784
HCC1806 CTRP2 -2.8044 -1.315 -2.8044 58.9514
HMC-1-8 CTRP2 -2.7321 -1.9591 -2.7321 58.4705
HCC1395 CTRP2 -2.7176 0.6816 -2.7283 58.2294
JIMT-1 CTRP2 -2.6587 -1.8867 -2.6587 57.9811
MDA-MB-468 CTRP2 -2.5253 1.8174 -2.5764 56.7674
Hs 739.T CCLE -2.5095 2.264 -2.8289 47.6623
EFM-192A GDSC1 -2.4707 0.962 -2.9991 34.3211
HCC1937 GDSC1 -2.3587 -0.2412 -2.5075 30.8417
BT-549 GDSC1; CCLE -2.3189 -0.1342 -2.3283 45.7056
HDQ-P1 GDSC1; CCLE -2.3056 0.8521 -2.3755 45.7203
HMC-1-8 CCLE -2.2605 -1.1308 -2.2606 45.1789
HCC1395 GDSC1; CCLE -2.1155 2.4253 -2.4369 44.6289
MDA-MB-231 GDSC1 -1.7517 7.1272 -5.092 37.5665
BT-549 CTRP2 -1.4942 3.4435 -1.6459 50.2081
BT-20 CTRP2 -1.4703 4.5588 -1.804 50.0563
HCC1937 CTRP2 -1.2834 2.7544 -1.3504 48.8581
CAL-85-1 GDSC1; CCLE -1.2232 2.0958 -1.3973 36.9437
CAL-120 GDSC1 -1.1548 1.8345 -1.9804 20.6807
MDA-MB-175-VII GDSC1; CCLE -1.1456 1.3382 -1.202 35.8357
HDQ-P1 CTRP2 -1.1345 2.5537 -1.1805 47.8765
MDA-MB-415 GDSC1; CCLE 0.236 2.0184 0.184 23.9647
MDA-MB-436 GDSC1; CCLE 0.4189 4.6423 -0.3887 25.8497
ZR-75-1 CTRP2 0.4793 8.8342 -0.967 40.3189
Evsa-T GDSC1 1.468 3.0507 -0.5127 1.1532
CAL-51 GDSC1 1.5595 3.3333 -0.5841 1.4202
KPL-1 CTRP2 6.2959 8.5464 4.9964 3.9431
BT 145 CTRP2 -3.446 2.42 -3.5944 61.609
BT 245 CTRP2 -2.5429 0.3211 -2.5465 57.1592
BT 179 CTRP2 -2.4382 1.3785 -2.4643 56.3326
BT 172 CTRP2 -2.2156 4.9267 -2.6912 54.1138
BT 224 CTRP2 -1.8808 3.2195 -2.0288 52.5855
BT 416 CTRP2 -1.5071 1.6282 -1.5213 50.3057
BT 333 CTRP2 -1.3119 3.6702 -1.4822 49.0786
BT164 CTRP2 -0.8254 6.8056 -1.6737 46.6453
BT 216 CTRP2 -0.3164 2.827 -0.3496 42.4652
BT 112 CTRP2 -0.1792 9.319 -1.8564 44.0426
BT 330 CTRP2 0.0093 10.0891 -1.9616 43.4303
BT 131 CTRP2 0.4999 4.5375 0.3283 37.4526
BT 159 CTRP2 0.5261 7.9564 -0.5903 39.467
BT 239 CTRP2 0.5752 7.2204 -0.2823 38.6532
BT 248 CTRP2 0.8003 8.8078 -0.6145 38.4941
BT 504 CTRP2 0.8933 9.2423 -0.6867 38.3005
BT 139 CTRP2 0.9551 6.6058 0.3274 35.7659
BT 320 CTRP2 0.9854 4.6931 0.825 34.2199
BT147 CTRP2 1.1093 10.1465 -0.8301 37.8242
BT 286 CTRP2 1.308 14.0179 -2.3495 39.6051
BT 359 CTRP2 1.7343 10.0477 -0.1379 34.2666
BT 228 CTRP2 1.8826 6.7109 1.3045 29.6737
BT 498 CTRP2 2.4059 6.2762 2.0079 25.6223
BT 232 CTRP2 2.4949 9.7417 0.7804 29.4224
BT 340 CTRP2 2.8639 12.5141 -0.1128 30.8384
BT 231 CTRP2 3.1383 15.6821 -1.3685 32.9518
BT 444 CTRP2 3.3704 9.5147 1.7758 23.6488
BT 440 CTRP2 3.548 8.248 2.5126 20.4528
BT 187 CTRP2 3.5507 13.0993 0.2714 27.9696
BT 422 CTRP2 4.2476 24.1117 -4.5271 35.4702
BT 482 CTRP2 5.46 12.7203 2.2077 17.0137
BT 328 CTRP2 8.6714 21.5825 0.3411 17.4549
⏷ Show the Full List of 123 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 -2.8259 -1.6092 -2.8259 59.0948
Cancer Drug Sensitivity Data Curated from 101 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
D283 Med CTRP2 -9.4136 -6.8217 -9.4136 95.9037
D283 Med GDSC1 -6.3111 -5.6728 -6.3111 79.3038
U-251MG GDSC1 -5.8386 -4.5084 -5.8387 73.1883
D-566MG GDSC1 -5.4172 -3.8463 -5.4179 67.8973
Daoy CTRP2 -5.1219 -2.3979 -5.1222 74.0289
GI-1 GDSC1; CCLE -5.0893 -3.4451 -5.0893 69.4173
SF268 GDSC1 -5.0754 -3.3438 -5.0778 63.6371
M059K CTRP2 -4.9837 -1.5149 -4.9866 72.6681
KNS-60 CTRP2 -4.9688 -2.5676 -4.9689 73.1864
CAS-1 CTRP2 -4.9573 2.8038 -5.2578 67.7576
D-423MG GDSC1 -4.9374 -3.1782 -4.9407 61.9405
PFSK-1 GDSC1 -4.8777 -2.9404 -4.8844 61.1139
Hs 683 CTRP2 -4.7398 -0.4494 -4.7553 70.4834
Daoy GDSC1; CCLE -4.7221 -2.2988 -4.7241 66.0613
A-172 CTRP2 -4.7212 -0.2613 -4.7413 70.2137
MOG-G-UVW GDSC1 -4.69 -2.3398 -4.7155 58.6023
AM-38 CTRP2 -4.6553 -0.687 -4.665 70.2571
GaMG GDSC1; CCLE -4.6393 -3.5082 -4.6393 65.6059
KNS-60 CCLE -4.6323 -2.4839 -4.6331 65.4135
U-118MG CTRP2 -4.6007 1.3487 -4.7049 67.9886
AM-38 GDSC1 -4.5056 -2.8396 -4.5094 56.6728
CAS-1 GDSC1; CCLE -4.4348 -1.4573 -4.446 63.3903
Becker CTRP2 -4.4244 1.378 -4.5228 67.1765
YH-13 GDSC1 -4.2842 -1.9007 -4.324 53.7831
SF268 CTRP2 -4.24 -2.2887 -4.24 68.4874
Becker GDSC1 -4.2169 -1.3619 -4.312 52.8616
42-MG-BA GDSC1; CCLE -4.2014 -2.4006 -4.2016 61.8168
GB-1 GDSC1; CCLE -4.08 -1.0537 -4.096 60.4505
SW1783 GDSC1 -4.051 -1.8895 -4.0814 51.0288
KINGS-1 GDSC1 -4.0477 -2.5401 -4.0513 51.0184
MOG-G-CCM GDSC1; CCLE -4.006 -1.4923 -4.011 60.0215
YH-13 CTRP2 -3.9475 0.6015 -3.9804 65.5067
YKG-1 GDSC1; CCLE -3.9424 -2.395 -3.9425 59.6155
D-336MG GDSC1 -3.931 -1.845 -3.9597 49.5774
H4 GDSC1; CCLE -3.9208 -3.0365 -3.9208 59.4374
SK-MG-1 GDSC1 -3.8872 -2.0365 -3.903 49.0344
SNU-466 CTRP2 -3.8669 -1.5968 -3.867 65.9814
LN-18 GDSC1; CCLE -3.7563 -2.5181 -3.7563 58.0241
LN-229 GDSC1; CCLE -3.7401 -1.3053 -3.7452 57.7942
LN-405 GDSC1 -3.7074 -1.3216 -3.7745 46.9299
DK-MG GDSC1; CCLE -3.6629 -0.8829 -3.6759 57.0688
A-172 GDSC1; CCLE -3.6587 -2.7289 -3.6587 57.1862
D-263MG GDSC1 -3.6437 -1.3553 -3.7029 46.1458
DK-MG CTRP2 -3.6094 1.2015 -3.6621 63.2799
D-392MG GDSC1 -3.5781 -1.8615 -3.5933 45.2137
KG-1-C CTRP2 -3.5681 -0.0095 -3.5766 63.6898
SF295 CTRP2 -3.5538 -0.5026 -3.5565 63.7678
U-118MG GDSC1; CCLE -3.4911 -0.7795 -3.5038 55.64
D-542MG GDSC1 -3.4666 -1.4572 -3.5055 43.9227
1321N1 CCLE -3.4395 -0.4896 -3.4615 55.1626
SF295 GDSC1; CCLE -3.4256 -2.2877 -3.4256 55.1842
ONS-76 CTRP2 -3.3933 -1.0591 -3.3936 62.8393
D-247MG GDSC1 -3.38 -1.7992 -3.3924 42.74
D-502MG GDSC1 -3.2386 -0.511 -3.4048 41.6434
8-MG-BA GDSC1; CCLE -3.2059 -1.5913 -3.2062 53.2951
M059J GDSC1; CCLE -3.2033 -0.9205 -3.2086 53.2509
Hs 683 GDSC1; CCLE -3.1544 -1.1469 -3.1566 52.8457
SNU-1105 CTRP2 -3.1261 -0.7798 -3.1265 61.0667
ONS-76 GDSC1; CCLE -3.1147 -1.1114 -3.1169 52.5057
KS-1 [Human Krukenberg tumour] GDSC1 -3.0104 0.9907 -3.5913 40.5262
NMC-G1 GDSC1 -3.0067 -0.3297 -3.1926 38.9597
LN-18 CTRP2 -2.9256 -2.2339 -2.9256 59.7595
SNB-75 GDSC1 -2.9048 0.0715 -3.1835 38.1701
SF126 CTRP2 -2.792 -0.4108 -2.7926 58.847
U-251MG CTRP2 -2.7653 0.1264 -2.7685 58.6237
DBTRG-05MG GDSC1; CCLE -2.7542 -0.323 -2.7663 49.4243
KALS-1 GDSC1; CCLE -2.7496 0.3367 -2.7957 49.398
GB-1 CTRP2 -2.7236 0.7172 -2.7351 58.26
TM-31 CTRP2 -2.6843 1.3115 -2.714 57.8742
SNU-738 CTRP2 -2.606 -0.4234 -2.6064 57.6206
LN-229 CTRP2 -2.573 2.1718 -2.6514 56.9472
GaMG CTRP2 -2.573 -0.0043 -2.5745 57.3826
SF126 GDSC1; CCLE -2.572 0.5714 -2.6291 47.9259
KNS-81 CCLE -2.5402 0.3053 -2.5756 47.6339
Onda 10 GDSC1 -2.5396 0.0066 -2.7671 33.5308
T98G GDSC1; CCLE -2.4671 -0.9055 -2.4677 46.9544
SW1088 GDSC1; CCLE -2.4337 -0.0309 -2.4487 46.6984
SF539 GDSC1 -2.3554 0.196 -2.6196 31.4998
GOS-3 CTRP2 -2.3261 3.917 -2.6101 54.9889
U-87MG ATCC CTRP2 -2.2874 2.247 -2.3589 55.2176
GMS-10 CCLE -2.1939 0.8977 -2.2623 44.7808
SNU-201 CTRP2 -2.1652 3.4195 -2.3587 54.2226
LNZTA3WT4 GDSC1 -2.155 -0.3145 -2.2696 28.0957
SNU-626 CTRP2 -2.1256 -0.2936 -2.1256 54.4282
SNU-489 CTRP2 -1.9908 2.4492 -2.0652 53.3615
SF539 CTRP2 -1.9357 5.2942 -2.4717 52.576
T98G CTRP2 -1.9099 0.6593 -1.9125 52.9825
KNS-81-FD GDSC1 -1.7927 0.7288 -2.1846 25.4281
GMS-10 CTRP2 -1.7594 1.0065 -1.7645 51.9798
U-87MG ATCC GDSC1; CCLE -1.5089 1.1815 -1.569 38.9534
42-MG-BA CTRP2 -1.4796 1.3326 -1.4867 50.1252
KNS-42 GDSC1; CCLE -1.0548 1.1767 -1.0916 34.9784
DBTRG-05MG CTRP2 -1.0177 2.3017 -1.0456 47.0902
KALS-1 CTRP2 -1.0008 5.728 -1.5602 47.4239
SW1088 CTRP2 -0.474 3.5428 -0.5745 43.6494
8-MG-BA CTRP2 -0.3811 3.3479 -0.4564 42.9897
SNB-75 CTRP2 -0.1916 9.3873 -1.8961 44.1315
Onda 11 GDSC1 0.3198 2.8196 -1.1282 8.1746
SW1783 CTRP2 0.6863 24.1149 -7.7694 45.1786
KNS-81 CTRP2 0.9153 5.3022 0.6306 35.0588
CCF-STTG1 CTRP2 1.1021 7.3444 0.2471 35.4486
⏷ Show the Full List of 101 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC1 -4.3346 -1.7454 -4.3911 54.3068
TGBC24TKB GDSC1 -3.2844 -1.1567 -3.3454 41.7742
TGBC1TKB GDSC1 -2.7997 -0.7798 -2.8803 35.8968
Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-6 CTRP2 -7.9455 2.5269 -8.4267 76.0536
RL95-2 CTRP2 -6.2353 -5.0315 -6.2353 81.7844
HEC-151 CCLE -5.4479 -1.8937 -5.4653 70.8234
JHUEM-2 CCLE -5.4098 -1.6839 -5.4335 70.3109
HEC-6 CCLE -5.2254 -3.6402 -5.2254 70.5875
JHUEM-3 CTRP2 -5.1513 3.5851 -5.6009 67.5354
RL95-2 GDSC1; CCLE -5.1421 -3.3288 -5.1422 69.8257
MFE-319 GDSC1; CCLE -5.0761 -3.441 -5.0762 69.3071
JHUEM-1 CTRP2 -4.9934 -1.3364 -4.9978 72.5749
HEC-1-B CCLE -4.7472 -2.8607 -4.7474 66.4568
HEC-1-A CCLE -4.6175 -2.3742 -4.6186 65.2572
ESS-1 GDSC1; CCLE -4.5904 -3.4197 -4.5904 65.1859
KLE CTRP2 -4.4833 4.371 -5.0349 64.4057
MFE-280 GDSC1; CCLE -4.3596 -1.0869 -4.3808 62.596
EN GDSC1; CCLE -4.3129 0.5949 -4.4759 60.9391
HEC-1-A CTRP2 -4.2127 -1.6688 -4.213 68.2092
JHUEM-2 CTRP2 -4.2101 2.2257 -4.3817 65.3848
ESS-1 CTRP2 -4.1075 -0.0544 -4.1225 66.8312
MFE-296 GDSC1; CCLE -4.089 0.9378 -4.2866 59.2337
HEC-151 CTRP2 -3.9537 -0.0735 -3.966 65.9805
MFE-319 CTRP2 -3.9421 -0.6093 -3.9463 66.1839
HEC-265 CCLE -3.9235 -2.8719 -3.9235 59.4599
HEC-59 CCLE -3.9139 -2.9234 -3.9139 59.3777
AN3-CA GDSC1; CCLE -3.8176 -0.1353 -3.874 58.0088
KLE GDSC1; CCLE -3.6126 -0.5758 -3.6355 56.5819
JHUEM-7 CTRP2 -3.5893 5.7221 -4.3829 59.9521
HEC-1-B CTRP2 -3.5472 -0.0133 -3.5554 63.5652
HEC-59 CTRP2 -3.4175 -1.3361 -3.4176 63.0187
HEC-251 CCLE -2.91 1.1492 -3.055 50.6946
HEC-108 CTRP2 -2.6805 0.3077 -2.6849 58.0523
AN3-CA CTRP2 -2.652 4.6048 -3.0955 56.4297
EFE-184 CCLE -2.5644 0.0488 -2.5863 47.8215
EN CTRP2 -2.4706 6.3224 -3.3256 54.9274
TEN CCLE -2.382 -1.3091 -2.3821 46.2222
HEC-265 CTRP2 -2.0407 1.1544 -2.0518 53.8188
MFE-296 CTRP2 -1.6734 6.2484 -2.4349 51.1027
HEC-251 CTRP2 -1.6566 2.2565 -1.7031 51.2669
EFE-184 CTRP2 -0.8302 3.1487 -0.9098 45.9333
HEC-50B CTRP2 1.6801 6.3382 1.1982 30.6789
Ishikawa (Heraklio) 02 ER- CCLE -5.3453 -2.969 -5.3462 71.2454
Ishikawa (Heraklio) 02 ER- CTRP2 -3.1366 -2.2554 -3.1366 61.1652
⏷ Show the Full List of 41 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 54 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KTCTL-21 GDSC1 -5.2436 -2.5014 -5.2794 64.5295
VMRC-RCZ GDSC1; CCLE -5.0668 -3.0026 -5.0672 69.1041
LB1047-RCC GDSC1 -4.9965 -3.5477 -4.9972 62.7977
769-P GDSC1; CCLE -4.9395 -2.4516 -4.9415 67.8327
KTCTL-140 GDSC1 -4.7935 -2.0668 -4.8433 59.5016
SW13 GDSC1 -4.6911 -2.3337 -4.7171 58.6107
CAL-54 GDSC1 -4.4989 -3.0535 -4.5003 56.6305
RXF 393L GDSC1 -4.4361 -1.9882 -4.4757 55.5551
KTCTL-13 GDSC1 -4.4339 -1.316 -4.5507 55.182
Caki-1 GDSC1 -4.2011 -1.8335 -4.2426 52.8001
NCC021 GDSC1 -4.043 -0.5494 -4.2707 50.8213
VMRC-RCW GDSC1; CCLE -4.0195 -1.8117 -4.0213 60.2067
TK-10 GDSC1 -3.9622 -0.1651 -4.2744 49.9633
ACHN GDSC1; CCLE -3.7169 -0.6989 -3.7374 57.4521
OS-RC-2 CTRP2 -3.6624 0.582 -3.6877 63.9515
HA7-RCC GDSC1 -3.557 -0.5713 -3.7378 45.4081
TUHR14TKB CTRP2 -3.51 3.6754 -3.8445 61.0319
Caki-2 CCLE -3.4382 -2.5207 -3.4382 55.2929
BFTC-909 GDSC1; CCLE -3.4343 -1.1646 -3.4384 55.2197
Caki-1 CTRP2 -3.3245 1.3975 -3.3787 61.5973
BB65-RCC GDSC1 -3.2883 -1.0626 -3.3618 41.8746
KTCTL-26A GDSC1 -3.2798 -1.1306 -3.3438 41.7305
UO-31 CTRP2 -3.2758 0.3717 -3.2879 61.7796
KTCTL-195 GDSC1 -3.2636 0.0306 -3.5638 42.3956
A-704 GDSC1 -3.2276 1.1444 -3.8803 42.9859
TUHR10TKB CTRP2 -3.1019 -0.1933 -3.1045 60.8381
769-P CTRP2 -2.9897 -0.5618 -2.9903 60.1557
RCC10RGB GDSC1 -2.9741 0.7893 -3.4822 39.8837
KTCTL-1M GDSC1 -2.8905 -0.6674 -2.9971 37.159
SW156 GDSC1 -2.8848 0.4645 -3.2786 38.4394
BFTC-909 CTRP2 -2.6883 1.5491 -2.7295 57.8304
OS-RC-2 GDSC1 -2.6357 1.8042 -3.4997 37.6022
ACHN CTRP2 -2.6304 0.4864 -2.6366 57.7055
LB996-RCC GDSC1 -2.6051 -0.7909 -2.6701 33.3901
KMRC-20 GDSC1 -2.5392 1.2631 -3.1847 35.6559
A-498 GDSC1 -2.4654 0.5079 -2.8364 33.4345
SN12C GDSC1 -2.4478 -1.158 -2.4647 31.1308
LB2241-RCC GDSC1 -2.4157 -0.6595 -2.487 31.0695
TUHR4TKB CTRP2 -2.3807 2.2635 -2.4578 55.777
UO-31 GDSC1 -2.2551 0.9295 -2.7553 31.6618
KMRC-2 CCLE -2.2173 2.75 -2.6275 45.5489
SNU-1272 CTRP2 -2.1523 8.6536 -3.7283 52.9593
KMRC-2 CTRP2 -2.1478 5.8345 -2.8395 53.5437
786-O GDSC1; CCLE -2.1415 -0.2389 -2.146 44.1717
VMRC-RCW CTRP2 -2.1339 0.7464 -2.139 54.4548
VMRC-RCZ CTRP2 -1.8621 1.6101 -1.8832 52.628
KMRC-20 CTRP2 -1.8268 2.0436 -1.8667 52.3704
A-498 CTRP2 -1.8119 0.8105 -1.8152 52.3308
KMRC-1 CTRP2 -1.7679 1.8663 -1.797 52.0029
786-O CTRP2 -1.7254 2.6384 -1.8033 51.6844
RCC10RGB CTRP2 -1.7008 2.5252 -1.7682 51.5362
KMRC-1 GDSC1; CCLE -1.5838 0.91 -1.6231 39.5178
Caki-2 CTRP2 -1.255 2.3806 -1.2947 48.6587
KMRC-3 CTRP2 -0.4934 5.5062 -0.951 44.3446
⏷ Show the Full List of 54 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 98 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-C1 CTRP2 -7.8254 -5.9564 -7.8254 91.0853
SW948 CTRP2 -7.5894 -5.5315 -7.5894 89.5383
SNU-C1 GDSC1 -6.9959 -4.8602 -6.9973 84.0719
HT115 CTRP2 -6.6068 -5.4187 -6.6068 84.2384
SNU-61 GDSC1 -6.5678 -0.388 -7.06 69.0294
COLO205 GDSC1; CCLE -6.3746 -5.8195 -6.3746 80.5105
GP2d CTRP2 -6.3169 -2.1915 -6.3221 79.6396
HCT 116 GDSC1; CCLE -6.2991 -4.5118 -6.2991 79.4819
SW48 CTRP2 -6.1881 -4.5982 -6.1881 81.3918
LS411N GDSC1; CCLE -6.1586 -4.8429 -6.1586 78.5756
OUMS-23 CTRP2 -6.147 -5.4772 -6.147 81.2203
RCM-1 [Human ESC] CTRP2 -6.0061 -3.5588 -6.0062 79.7793
C2BBe1 CTRP2 -5.7703 -2.659 -5.771 77.7743
HT-29 GDSC1; CCLE -5.7004 -4.3957 -5.7004 74.6853
HCC-56 CTRP2 -5.6885 -1.6834 -5.6943 76.3244
CCK-81 CTRP2 -5.6651 -1.3555 -5.6751 75.8162
SNU-503 CTRP2 -5.4887 2.9978 -5.8602 69.3257
SW403 CCLE -5.4386 -2.832 -5.4406 71.8195
NCI-H747 GDSC1; CCLE -5.419 -3.6033 -5.4191 72.1626
MDST8 GDSC1 -5.3651 -4.3023 -5.3651 67.4632
COLO 320HSR GDSC1 -5.2039 -3.7097 -5.2045 65.3347
LS411N CTRP2 -5.1832 -3.2768 -5.1832 74.7263
CaR-1 GDSC1 -5.1798 -2.9071 -5.1931 64.4122
LoVo GDSC1 -5.1701 -3.1042 -5.1775 64.5143
SW620 GDSC1; CCLE -5.111 -4.2818 -5.111 69.6591
COLO201 CCLE -5.0951 -3.5416 -5.0951 69.4827
LoVo CTRP2 -5.0929 0.3547 -5.1478 71.2379
HT115 GDSC1 -5.0197 -3.7092 -5.0199 63.122
KM12 GDSC1 -4.9282 -2.8761 -4.9374 61.6449
SNU-407 GDSC1 -4.9248 -0.3562 -5.2763 58.8623
SW1417 CTRP2 -4.8202 -1.8862 -4.821 71.9941
CL-11 CTRP2 -4.814 -1.0817 -4.8197 71.4173
SW626 GDSC1 -4.7677 -2.9124 -4.7734 59.8238
CCK-81 GDSC1; CCLE -4.742 -3.1514 -4.742 66.4618
NCI-H716 GDSC1 -4.678 -1.0039 -4.8666 57.3764
LS513 CTRP2 -4.6628 -2.2838 -4.6629 71.1992
SNU-81 CTRP2 -4.6456 -1.1375 -4.6496 70.5435
SNU-1040 GDSC1 -4.6384 -1.2247 -4.7848 57.1874
COLO 678 CTRP2 -4.6327 2.2176 -4.8294 67.1776
HCC2998 GDSC1 -4.6121 -2.8821 -4.6164 57.9676
NCI-H508 CTRP2 -4.6048 -2.5216 -4.6048 70.8833
SW1463 CTRP2 -4.5814 2.095 -4.7601 67.1016
NCI-H747 CTRP2 -4.5503 -2.8839 -4.5503 70.5682
SNU-175 GDSC1 -4.5396 -1.8715 -4.5945 56.6422
LS513 GDSC1; CCLE -4.5258 -2.1908 -4.5276 64.4534
SW1417 GDSC1; CCLE -4.5241 -2.8098 -4.5242 64.5847
C2BBe1 CCLE -4.4824 -1.8737 -4.4867 63.9773
LS123 GDSC1; CCLE -4.4433 -2.6452 -4.4435 63.8841
CL-11 GDSC1 -4.4306 -2.7135 -4.4358 55.7372
COLO205 CTRP2 -4.4093 -2.1863 -4.4094 69.5701
SNU-C2B GDSC1; CCLE -4.3527 -0.5359 -4.4024 62.1502
SW48 GDSC1; CCLE -4.283 -2.2602 -4.2837 62.482
SW480 CCLE -4.2154 -3.2114 -4.2154 61.9671
SNU-C5 GDSC1 -4.1912 -1.6922 -4.2452 52.6537
HT-55 GDSC1 -4.1888 -2.8034 -4.1904 52.778
LS180 CTRP2 -4.0897 -1.5326 -4.0901 67.3997
SNU-1033 CTRP2 -3.9511 -0.9737 -3.9528 66.3766
HCC-56 CCLE -3.9295 -2.9536 -3.9295 59.5121
RCM-1 [Human ESC] GDSC1 -3.8814 -0.9418 -4.0176 49.0465
CW-2 CTRP2 -3.8616 0.4985 -3.8883 65.1116
COLO 320 CCLE -3.8434 -1.7768 -3.8447 58.7291
LS123 CTRP2 -3.8406 -0.8284 -3.8427 65.6476
LS180 GDSC1 -3.7831 -1.1978 -3.8715 47.8649
COLO201 CTRP2 -3.7364 -2.2281 -3.7364 65.1586
GP5d GDSC1 -3.6655 -1.6591 -3.6968 46.3415
HCT 8 CTRP2 -3.6367 -0.5138 -3.6398 64.2871
SW1463 GDSC1 -3.6183 -1.371 -3.6743 45.8306
SK-CO-1 CTRP2 -3.5527 -1.5972 -3.5528 63.924
LS1034 GDSC1 -3.5116 -1.2631 -3.5737 44.5536
T84 CTRP2 -3.499 0.6235 -3.5221 62.9959
SNU-C2A CTRP2 -3.409 1.7262 -3.4895 61.8691
SNU-407 CTRP2 -3.393 1.6236 -3.4651 61.8452
RKO GDSC1; CCLE -3.3107 -0.1303 -3.3472 54.0473
MDST8 CTRP2 -3.2866 -1.0095 -3.2868 62.1365
SNU-81 GDSC1 -3.2349 -1.062 -3.3049 41.2057
COLO 320 CTRP2 -3.1256 2.4861 -3.2628 59.9085
SNU-C5 CTRP2 -3.0954 1.0233 -3.1238 60.4521
HCT 116 CTRP2 -2.984 -1.7033 -2.984 60.1482
COLO 678 GDSC1; CCLE -2.8869 0.3338 -2.9388 50.537
SNU-61 CTRP2 -2.8347 -0.221 -2.836 59.1125
LS1034 CTRP2 -2.7683 1.0246 -2.7891 58.4681
SK-CO-1 CCLE -2.5875 -0.1115 -2.6032 48.0095
NCI-H716 CTRP2 -2.5845 6.4605 -3.4895 55.3889
SNU-C2A CCLE -2.5525 0.8543 -2.6366 47.7928
HT-29 CTRP2 -2.4491 -1.4753 -2.4491 56.5851
SW1116 GDSC1 -2.4483 0.9316 -2.9639 33.9977
DLD-1 CTRP2 -2.374 -0.8654 -2.374 56.084
SW620 CTRP2 -2.1932 -0.063 -2.1936 54.8753
KM12 CTRP2 -2.1675 0.738 -2.1728 54.6752
RKO CTRP2 -2.094 3.2977 -2.2659 53.8369
T84 GDSC1; CCLE -1.8511 0.7405 -1.889 41.7945
HT-55 CTRP2 -1.7896 0.8413 -1.793 52.1828
HCT 15 CTRP2 -1.0916 1.7226 -1.1013 47.5552
SNU-C4 CTRP2 -0.7765 4.827 -1.1059 45.903
SW948 GDSC1 -0.7552 6.6754 -3.9652 29.7855
HCT 15 GDSC1; CCLE 0.154 1.6051 0.1365 24.5175
SW837 GDSC1 0.4333 17.2985 -8.2676 36.3359
CW-2 GDSC1 2.5289 4.3673 -0.5667 0.5173
⏷ Show the Full List of 98 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1 -3.2459 0.5539 -3.6998 42.6573
Cancer Drug Sensitivity Data Curated from 43 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-1 GDSC1 -7.9143 -6.6433 -7.9143 94.659
JHH-1 CTRP2 -7.7554 -6.6081 -7.7554 91.6093
HuH-6 CTRP2 -7.0615 -4.7218 -7.0615 86.2161
SNU-182 CTRP2 -6.5971 -2.9366 -6.5987 81.8259
SNU-475 GDSC1; CCLE -6.1504 -3.1269 -6.154 76.8133
JHH-2 CTRP2 -5.1757 -1.5167 -5.1796 73.6782
Hep-G2 CTRP2 -4.9968 -1.4611 -5.0002 72.6959
Hep-G2 CCLE -4.9674 -1.7684 -4.9796 67.5155
JHH-4 CTRP2 -4.9111 -1.8983 -4.912 72.5275
Hep-G2/C3A GDSC1; CCLE -4.7987 -3.7325 -4.7987 66.9752
SNU-423 GDSC1; CCLE -4.7811 -1.2667 -4.8056 65.7555
JHH-4 GDSC1; CCLE -4.759 -2.6345 -4.7596 66.4904
PLC/PRF/5 CCLE -4.7445 -3.1624 -4.7446 66.4845
JHH-5 CCLE -4.7305 -3.314 -4.7305 66.3782
JHH-5 CTRP2 -4.6346 1.7157 -4.7748 67.7347
SNU-387 CTRP2 -4.5202 3.8835 -4.9751 65.0093
JHH-7 GDSC1; CCLE -4.417 -2.1448 -4.4186 63.5576
SNU-423 CTRP2 -4.4045 -0.5849 -4.413 68.8294
Hep 3B2.1-7 GDSC1; CCLE -4.2865 -2.5122 -4.2867 62.5472
SK-HEP-1 GDSC1; CCLE -4.0812 0.3664 -4.2001 59.5974
JHH-2 GDSC1; CCLE -4.0435 -1.5495 -4.0481 60.3431
HLE GDSC1; CCLE -3.9442 -1.7132 -3.9464 59.563
HuH-1 GDSC1; CCLE -3.8733 -1.6293 -3.8757 58.9579
SNU-182 CCLE -3.8502 -0.3167 -3.895 58.3408
JHH-6 GDSC1; CCLE -3.7696 0.215 -3.8543 57.4818
SNU-387 GDSC1; CCLE -3.6892 1.0286 -3.8718 56.4996
Li-7 CTRP2 -3.6551 0.0265 -3.6653 64.1939
HLF CTRP2 -3.4715 -0.8326 -3.4724 63.317
HLF CCLE -3.34 -1.129 -3.3437 54.4209
Hep 3B2.1-7 CTRP2 -3.08 -0.355 -3.0816 60.7217
HuH-1 CTRP2 -2.9306 0.0826 -2.9346 59.6947
SNU-449 GDSC1; CCLE -2.6141 0.7782 -2.6934 48.296
SK-HEP-1 CTRP2 -2.5913 0.814 -2.603 57.4039
SNU-886 CTRP2 -2.5641 -0.0453 -2.5654 57.3267
SNU-878 CTRP2 -2.3373 -1.2304 -2.3373 55.8401
SNU-449 CTRP2 -1.9543 2.4081 -2.0237 53.1403
SNU-398 CTRP2 -1.8943 3.1429 -2.0337 52.6769
PLC/PRF/5 CTRP2 -1.7667 -0.856 -1.7667 52.0385
SNU-398 GDSC1; CCLE -1.3142 1.2893 -1.3748 37.2938
SNU-761 CTRP2 -0.7408 2.6523 -0.7785 45.2806
SNU-475 CTRP2 0.545 6.3358 -0.0393 38.2227
Huh-7 GDSC1 0.7614 7.2248 -2.9745 19.377
JHH-6 CTRP2 1.0246 4.6018 0.8819 33.9052
⏷ Show the Full List of 43 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 339 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COR-L279 CTRP2 -10.3355 2.6027 -11.0232 79.4634
NCI-H810 CTRP2 -8.2572 -6.7679 -8.2572 93.9189
DV-90 CTRP2 -8.099 -5.7413 -8.099 91.5897
COR-L303 GDSC1 -7.9183 -4.9309 -7.9261 87.9692
HCC33 CTRP2 -7.6401 -2.8559 -7.6482 84.8943
NCI-H2171 CTRP2 -7.5232 -6.7884 -7.5232 90.3599
NCI-H1341 CTRP2 -7.4031 -6.914 -7.4031 89.5875
COR-L88 CTRP2 -7.2397 3.634 -7.8731 73.0759
NCI-H1734 CTRP2 -7.191 -3.0431 -7.1944 84.0408
NCI-H211 CTRP2 -7.1564 -5.5736 -7.1564 87.5714
COR-L88 GDSC1 -7.1323 -5.9328 -7.1323 88.2396
LB647-SCLC GDSC1 -6.9192 -4.5832 -6.9223 82.7178
COR-L321 GDSC1 -6.8579 -5.5932 -6.8579 85.1715
NCI-H526 GDSC1 -6.8062 -3.9273 -6.8203 79.9349
NCI-H2081 CTRP2 -6.7811 -2.908 -6.7835 82.4671
NCI-H1105 CTRP2 -6.7739 -4.0964 -6.774 84.1543
NCI-H146 GDSC1 -6.6972 -4.8325 -6.6978 81.9999
NCI-H69 CTRP2 -6.6635 -5.585 -6.6635 84.6319
COR-L311 GDSC1 -6.6282 -5.257 -6.6282 82.4153
DMS 454 CTRP2 -6.556 2.7456 -6.967 72.6989
NCI-H510A GDSC1 -6.5545 -4.7684 -6.555 80.7127
NCI-H1975 CTRP2 -6.5331 -4.7374 -6.5331 83.5224
VMRC-LCD CTRP2 -6.5176 -4.4937 -6.5176 83.2741
VMRC-LCD CCLE -6.4716 -5.0152 -6.4717 81.1337
DMS 273 CTRP2 -6.4649 -2.0929 -6.4723 80.0439
NCI-H526 CTRP2 -6.4112 -5.7075 -6.4112 82.9801
COLO 668 CTRP2 -6.4051 2.0108 -6.6911 73.3532
NCI-H810 GDSC1; CCLE -6.3813 -4.4409 -6.3813 80.0052
NCI-H187 GDSC1 -6.3587 -5.4807 -6.3587 79.8227
NCI-H522 CTRP2 -6.305 -2.7823 -6.3064 80.4183
HCC33 GDSC1 -6.2639 -4.8219 -6.264 78.1356
HCC1833 CTRP2 -6.2292 -4.0758 -6.2292 81.3803
MOR/CPR CTRP2 -6.1653 -5.673 -6.1653 81.3426
DMS 79 CTRP2 -6.1401 -4.935 -6.1401 81.1537
LC-1F CTRP2 -6.1095 -0.2801 -6.1633 75.9681
COR-L95 CTRP2 -6.0764 -3.5736 -6.0765 80.1729
NCI-H64 GDSC1 -6.0596 -5.4705 -6.0596 76.1696
HCC78 GDSC1; CCLE -6.0351 -4.2285 -6.0352 77.3062
NCI-H847 GDSC1 -6.0184 -4.8736 -6.0184 75.5041
SK-MES-1 CTRP2 -6.0048 -2.6049 -6.0061 78.8591
NCI-H720 GDSC1 -5.9768 -3.6615 -5.9838 73.3243
PC-14 CTRP2 -5.9734 -4.1179 -5.9734 79.9039
LK-2 GDSC1 -5.9679 -4.8669 -5.9679 74.9117
NCI-H889 CTRP2 -5.9029 -3.9515 -5.9029 79.4092
IST-SL2 GDSC1 -5.8402 -3.7111 -5.8447 72.1776
NCI-H1651 GDSC1; CCLE -5.8367 -4.3826 -5.8367 75.81
NCI-H1105 GDSC1 -5.8265 -4.9135 -5.8265 73.2285
NCI-H2029 CTRP2 -5.777 -2.6388 -5.7777 77.7887
NCI-H1915 CTRP2 -5.7734 -2.4264 -5.7747 77.5589
NCI-H1436 GDSC1 -5.7659 -3.672 -5.7702 71.3992
NCI-H2106 CTRP2 -5.7558 -4.0211 -5.7558 78.5253
SBC-5 GDSC1; CCLE -5.7441 -4.5668 -5.7441 75.0761
NCI-H1694 CTRP2 -5.7405 -2.6229 -5.7412 77.5885
NCI-H1770 GDSC1 -5.7121 -4.9739 -5.7121 71.8239
NCI-H1581 GDSC1; CCLE -5.705 -4.4592 -5.705 74.7335
NCI-H1092 CTRP2 -5.6724 1.1807 -5.8148 72.3357
NCI-H2347 GDSC1 -5.6445 -1.0498 -5.9044 65.2137
NCI-H661 GDSC1; CCLE -5.597 -2.9483 -5.5989 73.0456
NCI-H2141 CTRP2 -5.5962 0.8111 -5.7019 72.5883
NCI-H290 GDSC1 -5.5524 -3.8281 -5.5537 69.398
COR-L23 GDSC1; CCLE -5.5449 -3.0747 -5.546 72.7955
NCI-H1581 CTRP2 -5.5409 -3.7126 -5.5409 77.0931
PaCa-3 GDSC1 -5.5264 -4.1494 -5.5266 69.3506
NCI-H520 CTRP2 -5.4218 2.0814 -5.6517 70.2696
NCI-H23 CTRP2 -5.3856 -1.9725 -5.3876 75.1708
NCI-H209 CTRP2 -5.3793 14.4718 -9.4246 60.1258
NCI-H1184 CTRP2 -5.3764 -2.2784 -5.3772 75.3805
NCI-H524 CTRP2 -5.3428 -2.6511 -5.343 75.4506
LK2 CTRP2 -5.341 -4.5803 -5.341 75.8514
NCI-H1184 CCLE -5.3196 -3.6333 -5.3196 71.3646
NCI-H209 GDSC1 -5.3044 -3.1278 -5.3134 65.9729
NCI-H2110 CTRP2 -5.2953 -2.2557 -5.296 74.9219
NCI-H1568 CTRP2 -5.2894 -1.3966 -5.2953 74.1311
NCI-H2009 CTRP2 -5.2879 -3.2165 -5.2879 75.3715
PC-14 GDSC1; CCLE -5.2668 -3.3131 -5.267 70.8288
BEN GDSC1 -5.2421 -3.4297 -5.2449 65.5987
NCI-H2722 GDSC1 -5.1656 -2.6632 -5.189 63.9764
CPC-N GDSC1 -5.158 -4.1474 -5.1581 64.8905
NCI-H2126 CTRP2 -5.1508 -3.0256 -5.1508 74.4603
MOR/CPR CCLE -5.1418 -3.9737 -5.1418 69.9171
EPLC-272H GDSC1 -5.0936 -2.0941 -5.156 62.5279
NCI-H211 GDSC1; CCLE -5.0808 -3.877 -5.0808 69.3923
NCI-H1341 GDSC1; CCLE -5.0673 -4.2796 -5.0673 69.2835
NCI-H226 GDSC1; CCLE -5.0624 -4.2485 -5.0624 69.2414
HCC827 GDSC1; CCLE -5.0569 -2.2085 -5.0621 68.5382
IST-SL1 GDSC1 -5.0562 -3.5274 -5.0571 63.5043
NCI-H446 GDSC1 -5.04 -4.1545 -5.04 63.4241
NCI-H1836 GDSC1 -5.0374 -3.1467 -5.0421 63.0726
NCI-H2803 GDSC1 -5.0131 -3.7755 -5.0133 63.0555
NCI-H2170 CTRP2 -5.0112 -2.5289 -5.0114 73.4308
DMS 53 CTRP2 -5.0107 -2.1722 -5.0112 73.2584
COLO 677 CCLE -5.0094 -3.1355 -5.0095 68.6846
NCI-H1838 CTRP2 -5.0048 -0.7345 -5.0179 72.0694
NCI-H1435 CTRP2 -4.9974 -2.3145 -4.9977 73.2535
NCI-H1694 GDSC1; CCLE -4.9959 -4.0624 -4.9959 68.6698
EBC-1 GDSC1; CCLE -4.973 -2.1031 -4.9788 67.8435
EBC-1 CTRP2 -4.9488 -2.2578 -4.9491 72.938
GLC-82 CCLE -4.9463 -2.4476 -4.9484 67.8827
NCI-H1944 GDSC1; CCLE -4.943 -3.3676 -4.943 68.1808
NCI-H1666 CTRP2 -4.9419 -0.1882 -4.9687 71.1961
Lu-165 GDSC1 -4.913 -2.6152 -4.9313 61.2681
ABC-1 GDSC1 -4.9114 0.9236 -5.6297 57.4824
NCI-H2373 GDSC1 -4.8887 -3.4587 -4.8894 61.469
NCI-H2818 GDSC1 -4.8719 -3.1917 -4.8744 61.1766
SBC-3 GDSC1 -4.8588 -3.3316 -4.86 61.0712
NCI-H2135 GDSC1 -4.844 -2.5517 -4.8633 60.4608
DV-90 CCLE -4.8407 -1.3596 -4.863 66.2526
NCI-H2087 CTRP2 -4.8246 1.6881 -4.9723 68.5452
SBC-1 GDSC1 -4.8183 -3.4568 -4.8188 60.6117
LUDLU-1 CTRP2 -4.8089 -1.1516 -4.8138 71.4457
NCI-H647 GDSC1; CCLE -4.8017 -3.2685 -4.8017 66.9782
NCI-H1915 GDSC1; CCLE -4.8012 -2.8904 -4.8014 66.9097
NCI-H2029 GDSC1 -4.7951 -3.2999 -4.7963 60.2937
NCI-H2196 GDSC1 -4.7808 -2.8138 -4.789 59.9245
HOP-92 CTRP2 -4.7611 -1.4256 -4.7636 71.3813
HCC44 CTRP2 -4.7603 -2.1438 -4.7606 71.7545
NCI-H661 CTRP2 -4.7409 -1.4581 -4.7431 71.2885
EMC-BAC-2 GDSC1 -4.738 -3.0937 -4.7405 59.5437
ChaGo-K-1 GDSC1 -4.6621 -2.8136 -4.6684 58.538
NCI-H1155 CTRP2 -4.6331 -2.4709 -4.6331 71.0551
NCI-H322M GDSC1 -4.6222 -1.9355 -4.6753 57.5789
HCC15 CTRP2 -4.6216 -0.8392 -4.6286 70.1971
NCI-H2170 GDSC1; CCLE -4.6167 -3.235 -4.6167 65.4053
NCI-H1623 CTRP2 -4.5812 0.6682 -4.6365 68.6179
LUDLU-1 CCLE -4.5665 -2.8208 -4.5667 64.9435
NCI-H1623 GDSC1 -4.5665 -2.8154 -4.5715 57.4013
NCI-H69 GDSC1 -4.5571 -3.7066 -4.5571 57.391
NCI-H522 GDSC1; CCLE -4.55 -2.3361 -4.5512 64.6987
NCI-H345 GDSC1 -4.493 -2.7228 -4.4988 56.4922
ChaGo-K-1 CTRP2 -4.4885 0.8135 -4.5491 68.039
Ms-1 GDSC1 -4.487 -3.223 -4.4875 56.5014
NCI-H1876 GDSC1 -4.4869 -2.3534 -4.5052 56.2963
NCI-H196 CTRP2 -4.4831 -2.0831 -4.4833 70.0173
NCI-H2286 CCLE -4.4677 -2.8234 -4.4677 64.1102
NCI-H524 GDSC1 -4.453 -3.4549 -4.453 56.088
NCI-H1944 CTRP2 -4.452 -1.6717 -4.4527 69.6961
Lu-134-A GDSC1 -4.4332 -2.5147 -4.4437 55.7192
NCI-H650 GDSC1; CCLE -4.4326 -0.6951 -4.4751 62.8367
NCI-H2795 GDSC1 -4.4269 -2.8374 -4.4299 55.7149
NCI-H1155 GDSC1; CCLE -4.3805 -3.3886 -4.3805 63.3851
NCI-H2081 GDSC1 -4.3525 -2.7216 -4.3565 54.788
NCI-H520 GDSC1; CCLE -4.3514 -1.5609 -4.3592 62.8038
NCI-H2804 GDSC1 -4.343 -1.9096 -4.3847 54.4623
Sq-1 CCLE -4.3338 -2.1332 -4.3351 62.8745
NCI-H1975 GDSC1; CCLE -4.3243 -1.4584 -4.3338 62.5423
NCI-H3122 GDSC1 -4.3075 -1.1054 -4.4486 53.7518
NCI-H196 GDSC1 -4.2948 -3.4095 -4.2948 54.1124
NCI-H1781 GDSC1 -4.2802 0.1451 -4.705 52.9792
NCI-H82 GDSC1 -4.2619 -2.9317 -4.2629 53.6916
Hs 229.T CCLE -4.2605 0.281 -4.3802 60.8654
NCI-H2405 GDSC1 -4.2587 -1.982 -4.2911 53.5084
NCI-H1651 CTRP2 -4.24 -1.0782 -4.2422 68.1707
NCI-H23 GDSC1; CCLE -4.2397 -2.5044 -4.2398 62.1508
NCI-H1869 CTRP2 -4.2254 -0.0658 -4.242 67.4832
LCLC-103H GDSC1; CCLE -4.2113 -3.4522 -4.2113 61.9319
NCI-H446 CTRP2 -4.2085 -0.6671 -4.214 67.7776
NCI-H1339 CTRP2 -4.2084 -0.8426 -4.2122 67.8712
HCC366 CTRP2 -4.1952 -1.7347 -4.1955 68.114
DMS 273 GDSC1 -4.176 -1.5087 -4.2494 52.4385
NCI-H1048 GDSC1; CCLE -4.1531 -1.2193 -4.1656 61.0957
CAL-12T GDSC1; CCLE -4.1484 -1.9004 -4.1502 61.2919
NCI-H358 CTRP2 -4.135 -1.0621 -4.1369 67.5328
NCI-H1666 GDSC1; CCLE -4.121 -1.3094 -4.1307 60.8825
EPLC-272H CTRP2 -4.1126 2.9341 -4.372 64.2969
NCI-H1304 GDSC1 -4.0823 -2.9002 -4.0828 51.4549
RERF-LC-A1 CCLE -4.0643 -1.4261 -4.0709 60.4731
NCI-H1385 CTRP2 -4.0642 -1.5634 -4.0645 67.2443
NCI-H2141 GDSC1 -4.0529 -1.8295 -4.0879 51.0479
NCI-H2196 CTRP2 -4.0428 1.6094 -4.1428 65.1804
COLO 699 CTRP2 -4.0308 0.7376 -4.0722 65.8448
NCI-H1755 CTRP2 -4.023 -0.863 -4.0257 66.7761
NCI-H2444 GDSC1; CCLE -4.0158 -1.1604 -4.0275 59.991
IA-LM CTRP2 -4.0081 2.2188 -4.1669 64.4806
NCI-H2595 GDSC1 -3.983 -1.7191 -4.024 50.207
NCI-H1755 GDSC1 -3.9776 -2.6388 -3.9793 50.1471
RERF-LC-MS CTRP2 -3.9671 0.0673 -3.9827 65.9717
NCI-H1435 GDSC1 -3.952 -2.5898 -3.954 49.8282
Calu-3 GDSC1; CCLE -3.951 -0.7258 -3.9766 59.3019
NCI-H2731 GDSC1 -3.9502 -2.4589 -3.954 49.8063
NCI-H2342 CTRP2 -3.882 1.2698 -3.949 64.6642
HCC44 GDSC1; CCLE -3.8805 -1.6433 -3.8828 59.0203
NCI-H1693 CCLE -3.8771 -1.0862 -3.8883 58.8573
NCI-H647 CTRP2 -3.8627 -0.0468 -3.8742 65.4439
NCI-H841 CTRP2 -3.8588 -0.5673 -3.8629 65.6655
NCI-H441 GDSC1; CCLE -3.8459 -0.5367 -3.8776 58.4069
Calu-6 GDSC1; CCLE -3.8056 -1.966 -3.8061 58.4282
A-549 GDSC1; CCLE -3.799 -2.4474 -3.799 58.3896
Lu-99 CCLE -3.7885 -0.1093 -3.8456 57.7781
Calu-3 CTRP2 -3.7643 -0.9901 -3.7653 65.2146
NCI-H2810 GDSC1 -3.7632 -2.3237 -3.7671 47.4786
Lu-65 GDSC1 -3.7515 -0.6569 -3.9311 47.6178
NCI-H596 GDSC1 -3.7253 0.5107 -4.208 47.6657
NCI-H1339 CCLE -3.7203 -1.8949 -3.7208 57.6987
NCI-H1792 GDSC1; CCLE -3.7131 -1.4056 -3.7166 57.5868
NCI-H2369 GDSC1 -3.6874 -2.2388 -3.6921 46.5371
NCI-H292 CTRP2 -3.6622 -1.1909 -3.6626 64.6012
NCI-H460 GDSC1; CCLE -3.613 -2.6225 -3.613 56.7938
LCLC-97TM1 GDSC1 -3.6111 -1.4631 -3.6569 45.7147
NCI-H1573 GDSC1; CCLE -3.6073 -1.695 -3.6082 56.726
HCC827 CTRP2 -3.607 -0.839 -3.6082 64.1845
T3M-10 CCLE -3.6057 0.869 -3.7588 55.986
NCI-H1869 GDSC1; CCLE -3.5884 -1.0644 -3.5958 56.494
RERF-LC-A1 CTRP2 -3.5738 -0.5731 -3.5762 63.9121
NCI-H358 GDSC1; CCLE -3.5667 -1.2984 -3.5703 56.3474
NCI-H841 GDSC1 -3.5468 -0.8824 -3.6672 45.1424
NCI-H1648 GDSC1; CCLE -3.5198 -2.3791 -3.5198 55.9929
NCI-H2023 GDSC1; CCLE -3.515 -1.6489 -3.5158 55.9382
NCI-H2342 GDSC1 -3.5129 -0.1373 -3.7914 45.1286
LC-2/ad GDSC1 -3.5107 -1.4802 -3.5498 44.4658
HOP-62 CTRP2 -3.5099 1.6419 -3.5883 62.461
HCC1588 CTRP2 -3.505 -1.5245 -3.505 63.6056
NCI-H2066 GDSC1 -3.4966 -0.3309 -3.7259 44.8332
NCI-H838 CTRP2 -3.4951 0.9133 -3.5294 62.8209
NCI-H2228 GDSC1; CCLE -3.4682 -0.7325 -3.4819 55.4429
HCC2279 CTRP2 -3.4656 -2.0072 -3.4656 63.3557
NCI-H322 CCLE -3.4147 -1.5897 -3.4155 55.0811
SW1573 GDSC1; CCLE -3.4073 -1.8178 -3.4075 55.0235
RERF-LC-MS GDSC1; CCLE -3.4047 -0.6445 -3.42 54.9054
SBC-5 CTRP2 -3.3869 -2.9044 -3.3869 62.8328
NCI-H2405 CTRP2 -3.3726 2.8469 -3.569 60.9546
LCLC-103H CTRP2 -3.3609 -1.8231 -3.3609 62.658
NCI-H2110 GDSC1 -3.3336 -0.1083 -3.6033 43.0947
DMS 114 CTRP2 -3.2909 1.7648 -3.3692 61.2072
HCC2108 CTRP2 -3.2703 -1.1214 -3.2704 62.0368
HCC15 GDSC1; CCLE -3.2632 -1.1055 -3.2665 53.7687
NCI-H2461 GDSC1 -3.2417 -1.6079 -3.2596 41.0454
SHP-77 GDSC1; CCLE -3.2172 -0.7773 -3.2254 53.3586
NCI-H1573 CTRP2 -3.2036 0.435 -3.216 61.3182
Lu-99 CTRP2 -3.1753 1.4593 -3.2279 60.7245
NCI-H1437 GDSC1 -3.1694 1.533 -3.9612 42.7455
NCI-H1688 GDSC1 -3.1505 -1.199 -3.1984 40.063
COR-L105 GDSC1; CCLE -3.1483 0.3795 -3.2166 52.6564
HCC78 CTRP2 -3.1021 -2.1094 -3.1021 60.9352
NCI-H1373 CCLE -3.0946 0.2241 -3.1471 52.2438
HCC4006 CCLE -3.0437 0.7471 -3.1446 51.7785
LXF 289 GDSC1 -3.0363 -1.2574 -3.072 38.5838
BEN CTRP2 -3.0213 -2.3305 -3.0213 60.397
A-427 GDSC1 -3.0051 -0.4359 -3.1671 38.8307
NCI-H2085 GDSC1; CCLE -3.003 -0.2573 -3.0233 51.5257
NCI-H292 GDSC1 -2.9895 -0.8925 -3.0667 38.2239
CAL-12T CTRP2 -2.9654 -1.3598 -2.9654 60.0232
HARA [Human squamous cell lung carcinoma] GDSC1; CCLE -2.9483 0.3167 -3.0016 51.0426
SW1271 GDSC1; CCLE -2.938 -0.3663 -2.9525 50.983
T3M-10 CTRP2 -2.9258 2.3382 -3.0366 58.9003
LCLC-97TM1 CTRP2 -2.916 0.6371 -2.9286 59.4848
COLO 699 CCLE -2.906 0.936 -3.0215 50.6723
LOU-NH91 GDSC1; CCLE -2.8908 -0.9683 -2.8929 50.5901
HCC1195 CTRP2 -2.8783 -0.0392 -2.8809 59.3759
NCI-H2030 GDSC1; CCLE -2.8702 -0.5519 -2.8783 50.4116
LC-1/sq-SF CCLE -2.8638 -0.3385 -2.8777 50.3553
HCC2935 CCLE -2.8565 -0.7393 -2.8609 50.2954
SK-MES-1 GDSC1; CCLE -2.8352 -1.4667 -2.8353 50.1143
NCI-H2122 CTRP2 -2.8312 0.3301 -2.8372 59.0168
NCI-H2087 GDSC1; CCLE -2.826 -0.0415 -2.8512 50.0339
NCI-H727 GDSC1; CCLE -2.8242 3.0791 -3.3779 50.0152
DMS 53 GDSC1 -2.8165 1.0063 -3.3876 38.3956
HCC4006 CTRP2 -2.7858 0.6393 -2.7966 58.6687
Calu-1 CCLE -2.761 0.1494 -2.7947 49.4891
LXF 289 CTRP2 -2.7514 0.0973 -2.7543 58.5375
NCI-H1355 GDSC1; CCLE -2.7414 1.0548 -2.8617 49.3547
NCI-H838 GDSC1 -2.7347 -0.7717 -2.8118 35.0721
NCI-H1563 GDSC1; CCLE -2.6758 2.5118 -3.068 48.9417
NCI-H1650 GDSC1; CCLE -2.6745 -0.368 -2.6839 48.7437
HCC95 CTRP2 -2.6391 -1.3305 -2.6391 57.8509
NCI-H1299 GDSC1; CCLE -2.6386 -0.158 -2.6538 48.4434
NCI-H2009 GDSC1; CCLE -2.6248 -0.0979 -2.6419 48.328
NCI-H2291 GDSC1 -2.6081 7.3579 -6.0098 43.0098
LC-1/sq-SF CTRP2 -2.6055 2.0971 -2.6794 57.163
NCI-H3255 GDSC1; CCLE -2.5919 0.0171 -2.6131 48.0534
NCI-H1703 CTRP2 -2.59 1.2358 -2.6143 57.3106
SHP-77 CTRP2 -2.5878 0.0183 -2.5895 57.4782
NCI-H2030 CTRP2 -2.535 -1.2923 -2.535 57.1569
HCC1438 CTRP2 -2.4797 0.6043 -2.4861 56.7184
SW1271 CTRP2 -2.4779 1.7106 -2.521 56.5058
NCI-H1703 GDSC1; CCLE -2.3935 0.149 -2.4151 46.369
KNS-62 GDSC1; CCLE -2.3879 0.6517 -2.4431 46.3834
HOP-62 GDSC1 -2.3875 -0.2503 -2.5368 31.2013
Calu-6 CTRP2 -2.3749 0.2644 -2.3771 56.065
Sq-1 CTRP2 -2.3581 -0.5177 -2.3582 55.9767
COR-L105 CTRP2 -2.3449 3.3437 -2.54 55.2653
NCI-H322 CTRP2 -2.3313 1.4175 -2.3562 55.653
NCI-H650 CTRP2 -2.3311 1.741 -2.3711 55.5934
A-549 CTRP2 -2.3244 0.7442 -2.3314 55.6977
NCI-H2869 GDSC1 -2.2248 2.4627 -3.3489 34.429
NCI-H1650 CTRP2 -2.2196 1.8716 -2.2631 54.8749
LOU-NH91 CTRP2 -2.2029 0.6783 -2.2077 54.9104
NCI-H2291 CTRP2 -2.1802 7.3595 -3.3221 53.3442
NCI-H1395 CTRP2 -2.1411 4.7036 -2.5616 53.7807
NCI-H2172 GDSC1 -2.089 1.1324 -2.6538 30.0787
DMS 114 GDSC1; CCLE -1.9823 0.5938 -2.0153 42.8972
IA-LM GDSC1; CCLE -1.9619 0.441 -1.9851 42.6931
NCI-H1373 CTRP2 -1.831 3.0178 -1.952 52.307
NCI-H2228 CTRP2 -1.7183 2.6227 -1.7945 51.6407
RERF-LC-Sq1 GDSC1 -1.6953 9.4575 -6.1865 39.5124
HCC2935 CTRP2 -1.6738 1.627 -1.6914 51.4009
NCI-H2122 GDSC1; CCLE -1.6646 1.8242 -1.8245 40.5972
NCI-H2286 CTRP2 -1.649 1.7109 -1.6688 51.236
NCI-H1568 GDSC1; CCLE -1.5387 1.4672 -1.6345 39.3329
NCI-H1734 GDSC1 -1.4673 0.3253 -1.6923 20.2683
COLO 668 GDSC1 -1.4619 0.127 -1.6248 19.776
Lu-65 CTRP2 -1.456 4.797 -1.8373 49.9729
Lu-135 GDSC1 -1.4497 -0.3585 -1.4974 18.8544
NCI-H2171 GDSC1 -1.4447 -0.745 -1.4508 18.5247
Lu-139 GDSC1 -1.4422 -0.866 -1.4441 18.467
RERF-LC-Ad2 CTRP2 -1.4416 4.9816 -1.8616 49.8911
UMC-11 GDSC1 -1.4335 -0.6936 -1.442 18.4003
Lu-99A GDSC1 -1.4078 0.5131 -1.6921 19.94
HARA [Human squamous cell lung carcinoma] CTRP2 -1.3746 3.9264 -1.5878 49.4754
NCI-H1838 GDSC1 -1.3546 5.7325 -4.0415 32.6696
EKVX GDSC1 -1.3518 3.336 -2.8775 27.3556
NCI-H1993 GDSC1 -1.2878 4.1046 -3.1858 28.6711
NCI-H513 GDSC1 -1.1793 3.062 -2.5806 24.7758
RERF-LC-KJ GDSC1 -1.1567 3.2522 -2.65 25.0889
NCI-H1793 CTRP2 -1.0784 3.8331 -1.2559 47.6252
NCI-H1355 CTRP2 -1.0623 6.5206 -1.8465 47.8885
NCI-H1793 GDSC1 -1.0143 1.012 -1.4714 16.3078
SK-LU-1 GDSC1; CCLE -0.9825 0.8591 -0.9969 34.2637
NCI-H1792 CTRP2 -0.8939 4.4297 -1.1557 46.5526
KNS-62 CTRP2 -0.8249 5.4176 -1.2909 46.3315
NCI-H460 CTRP2 -0.7887 2.9982 -0.8529 45.6392
NCI-H2172 CTRP2 -0.7159 5.6309 -1.2246 45.7315
NCI-H2444 CTRP2 -0.6825 1.8553 -0.6894 44.8326
NCI-H2085 CTRP2 -0.6778 3.5362 -0.7897 44.9941
NCI-H2023 CTRP2 -0.6278 1.4844 -0.6296 44.4559
NCI-H727 CTRP2 -0.4513 6.7871 -1.2605 44.5401
NCI-H441 CTRP2 -0.4307 4.3789 -0.647 43.5838
HCC1171 CTRP2 -0.4025 4.8239 -0.6996 43.5433
SK-LU-1 CTRP2 -0.3487 2.5226 -0.3681 42.6447
NCI-H226 CTRP2 -0.1656 2.8878 -0.1971 41.4612
NCI-H2591 GDSC1 -0.1516 4.3475 -2.2792 18.372
NCI-H1299 CTRP2 0.0948 3.8396 -0.0061 39.9224
SW900 CCLE 0.1557 2.2249 0.0681 24.8117
NCI-H1563 CTRP2 0.3489 7.6996 -0.6907 40.3393
Calu-1 CTRP2 0.3643 8.2765 -0.8807 40.6117
RERF-LC-Ad1 CTRP2 0.499 5.9465 0.019 38.2615
EMC-BAC-1 GDSC1 0.5066 14.1751 -6.6466 33.2689
NCI-H1092 GDSC1; CCLE 0.5306 3.1665 0.2578 22.4405
EKVX CTRP2 1.9842 11.2281 -0.3987 34.0937
Hs 888.Lu CTRP2 -5.65 2.2664 -5.9202 70.7778
⏷ Show the Full List of 339 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1 -4.0919 -1.7795 -4.1328 51.5074
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
P-STS CTRP2 -7.7142 -6.1907 -7.7142 90.9585
SYO-1 CTRP2 -6.3031 -2.7859 -6.3045 80.4149
H-STS CTRP2 -5.1084 -4.0295 -5.1084 74.3005
Cancer Drug Sensitivity Data Curated from 47 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 -4.5017 -0.883 -4.5072 69.5716
Aska-SS CTRP2 -4.1289 -0.2561 -4.1399 67.0809
Rh41 GDSC1 -7.1092 -5.9473 -7.1092 88.0994
Hs 633.T GDSC1 -6.7501 -5.3287 -6.7501 83.6548
Rh41 CTRP2 -6.6781 -4.9266 -6.6781 84.4663
Rh30 GDSC1; CCLE -6.4711 -5.2257 -6.4711 81.236
G-401 CTRP2 -6.0981 -2.573 -6.0997 79.2463
KYM-1 GDSC1; CCLE -5.792 -3.379 -5.7927 74.8328
RD CTRP2 -5.621 -2.4851 -5.6218 76.8478
TE 617.T CTRP2 -5.4737 -1.6116 -5.4787 75.247
TE 617.T CCLE -5.3628 -3.323 -5.363 71.5933
EW-8 GDSC1 -5.2091 -3.6054 -5.2102 65.3413
SK-LMS-1 GDSC1; CCLE -5.121 -2.8471 -5.1218 69.4579
SW872 GDSC1 -4.9679 -3.307 -4.97 62.3623
A-204 CTRP2 -4.9228 2.5547 -5.1837 67.9185
G-401 GDSC1; CCLE -4.8783 -1.6766 -4.8914 66.8066
SW982 GDSC1 -4.8097 -3.6153 -4.8098 60.5295
Rh18 GDSC1 -4.7816 -2.2281 -4.8178 59.5168
RD GDSC1; CCLE -4.7267 -2.5582 -4.7275 66.2031
Tm87-16 CTRP2 -4.6991 0.2397 -4.7365 69.609
Rh18 CTRP2 -4.6666 -0.9424 -4.6726 70.5182
HT-1080 CTRP2 -4.6238 -0.6474 -4.6338 70.0587
SW684 GDSC1 -4.3949 0.723 -5.0037 53.7255
GCT GDSC1; CCLE -4.3735 -1.4218 -4.3846 62.9023
KYM-1 CTRP2 -4.2428 -1.8049 -4.243 68.4315
SW982 CTRP2 -4.1843 -0.5436 -4.1912 67.5687
MFH-ino GDSC1 -3.9819 -2.106 -3.9972 50.1973
SK-UT-1 GDSC1 -3.9762 -1.7318 -4.0157 50.1247
G-402 CTRP2 -3.7789 1.8077 -3.8834 63.7254
TE 441.T GDSC1 -3.5424 -0.8585 -3.6666 45.1008
MES-SA GDSC1; CCLE -3.5195 -1.8863 -3.5198 55.9856
G-402 GDSC1; CCLE -3.2732 -0.3037 -3.299 53.7704
TTC-709 CTRP2 -3.2653 3.8103 -3.6044 59.8082
VA-ES-BJ GDSC1 -3.1681 -0.8689 -3.2619 40.4955
HT-1080 GDSC1; CCLE -3.0765 -0.8715 -3.0812 52.1732
Hs 729.T CCLE -2.7384 3.3312 -3.356 49.4381
A-204 GDSC1; CCLE -2.673 1.7529 -2.9007 48.8561
GCT CTRP2 -2.6427 1.9839 -2.7096 57.4195
RKN GDSC1; CCLE -2.6114 -0.5193 -2.6167 48.2001
SK-LMS-1 CTRP2 -2.271 1.3187 -2.291 55.2856
SK-UT-1 CTRP2 -1.8317 5.7121 -2.4626 51.9716
MES-SA CTRP2 -1.46 3.573 -1.6268 49.9957
Hs 729.T CTRP2 -1.3486 10.0623 -3.3906 49.5381
BT-12 CTRP2 -1.3292 1.3736 -1.3353 49.1281
RKN CTRP2 -1.0506 1.533 -1.0562 47.2771
BT-16 CTRP2 -0.9727 4.3108 -1.2194 47.025
TE 441.T CTRP2 8.0109 9.1114 5.6923 0.0651
⏷ Show the Full List of 47 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 -4.1433 0.7281 -4.1877 66.4313
Cancer Drug Sensitivity Data Curated from 79 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 -2.5151 1.3332 -2.5414 56.8227
EFO-27 CTRP2 -6.4087 -0.2977 -6.4712 76.9555
COV644 CTRP2 -6.2694 2.125 -6.5622 72.817
EFO-27 GDSC1; CCLE -5.7313 -3.2594 -5.7323 74.2908
OAW28 CTRP2 -5.6102 -0.636 -5.6363 74.6449
OVCAR-8 GDSC1; CCLE -5.557 -2.495 -5.563 72.2755
A2780 CTRP2 -5.3087 -1.4201 -5.3145 74.2492
OVCAR-5 GDSC1 -5.2482 -2.543 -5.2815 64.634
COV434 CTRP2 -5.2332 -2.1914 -5.234 74.5337
OVCAR-3 GDSC1; CCLE -5.2065 -3.4779 -5.2065 70.3942
OVCAR-5 CTRP2 -5.1374 -1.3623 -5.1425 73.3409
IGROV-1 GDSC1; CCLE -4.9848 -0.8818 -5.036 66.6824
Kuramochi GDSC1; CCLE -4.973 -3.1568 -4.9731 68.3915
OVK18 CTRP2 -4.8875 -1.4716 -4.8903 72.1136
FU-OV-1 GDSC1; CCLE -4.8782 0.1696 -5.0225 64.788
A2780 GDSC1; CCLE -4.5621 -2.5045 -4.5626 64.8449
FU-OV-1 CTRP2 -4.554 4.0395 -5.0427 64.9804
ES-2 GDSC1; CCLE -4.5132 -3.2786 -4.5132 64.5216
SK-OV-3 GDSC1; CCLE -4.4776 -2.5188 -4.478 64.15
TOV-112D CTRP2 -4.4055 -0.1901 -4.4219 68.5389
TOV-112D GDSC1; CCLE -4.3172 -2.9865 -4.3173 62.838
OC 314 CTRP2 -4.2964 -2.5193 -4.2964 68.8754
OV-90 GDSC1; CCLE -4.2809 -1.9977 -4.2828 62.405
OC 314 GDSC1; CCLE -4.1956 -2.149 -4.1964 61.7334
ONCO-DG-1 CTRP2 -4.1415 -1.9888 -4.1415 67.8125
HEY A8 CCLE -4.0331 -2.2741 -4.0333 60.3809
IGROV-1 CTRP2 -3.8416 -0.191 -3.8503 65.3956
OVCAR-8 CTRP2 -3.7954 1.6283 -3.8854 63.9472
OVISE GDSC1 -3.766 -2.9099 -3.7661 47.503
OVTOKO CTRP2 -3.7622 -0.2187 -3.7695 64.9391
OVTOKO GDSC1; CCLE -3.7249 -0.1289 -3.7778 57.3045
OC 315 CCLE -3.5986 -1.7599 -3.5992 56.6554
DOV13 GDSC1; CCLE -3.5135 -1.1515 -3.5185 55.8834
MCAS CCLE -3.5097 -1.8554 -3.5099 55.9006
TYK-nu GDSC1; CCLE -3.4979 -1.8966 -3.4981 55.8008
SNU-8 CTRP2 -3.369 -2.5835 -3.369 62.7137
RMG-I GDSC1 -3.3667 -1.7464 -3.3812 42.5848
JHOC-5 CTRP2 -3.2648 -1.1407 -3.2649 62.0021
ONCO-DG-1 CCLE -3.1917 -1.7872 -3.1918 53.1752
TOV-21G GDSC1; CCLE -3.1422 -0.2034 -3.169 52.68
OV-90 CTRP2 -3.1028 1.317 -3.145 60.3735
COV504 CCLE -3.0951 -0.7826 -3.1015 52.327
OC 316 CCLE -2.9879 -1.7868 -2.988 51.4256
RMG-I CTRP2 -2.9788 1.6623 -3.0369 59.5053
ES2 CTRP2 -2.8408 -1.6372 -2.8408 59.1941
OVCAR-4 GDSC1; CCLE -2.8265 -0.2282 -2.8435 50.0386
MCAS CTRP2 -2.6641 0.2398 -2.6677 57.9546
TYK-nu CTRP2 -2.6369 0.3984 -2.642 57.7594
OVMANA CCLE -2.6269 0.4394 -2.6756 48.3764
JHOS-2 GDSC1; CCLE -2.6027 1.6761 -2.8104 48.2976
SNU-840 CTRP2 -2.5983 1.7384 -2.6472 57.2306
OVKATE GDSC1 -2.5896 3.9873 -4.4024 40.073
COV318 CCLE -2.5709 0.9616 -2.6685 47.9572
SK-OV-3 CTRP2 -2.2217 0.3643 -2.2238 55.0518
OVISE CTRP2 -2.2172 -1.6239 -2.2172 55.0402
HEY A8 CTRP2 -2.2062 0.7133 -2.2115 54.9297
OVSAHO CCLE -2.1442 0.4204 -2.1723 44.263
EFO-21 CTRP2 -1.9357 3.4504 -2.1178 52.8798
JHOS-4 GDSC1; CCLE -1.8998 5.3207 -3.1215 44.4009
EFO-21 GDSC1; CCLE -1.8794 1.5209 -2.0063 42.2942
JHOM-1 CTRP2 -1.8357 1.7669 -1.8623 52.4472
JHOS-2 CTRP2 -1.6595 6.3912 -2.4603 51.0219
OV7 CTRP2 -1.5212 2.9502 -1.6177 50.3833
OVCAR-4 CTRP2 -1.5095 1.732 -1.5271 50.3215
TOV-21G CTRP2 -1.4188 3.5087 -1.5742 49.7401
Kuramochi CTRP2 -1.3531 3.5047 -1.5037 49.33
OAW42 GDSC1 -1.3057 1.055 -1.7935 20.1138
OAW42 CTRP2 -1.1294 2.0362 -1.1491 47.8173
OVSAHO CTRP2 -1.072 3.4011 -1.1919 47.5381
Caov-3 GDSC1 -1.0577 2.3916 -2.144 21.3506
Caov-3 CTRP2 -0.8542 9.4199 -2.6154 47.3131
OAW28 GDSC1 -0.638 4.1992 -2.6319 22.6258
SNU-119 CTRP2 0.1322 14.1878 -3.6053 44.4233
DOV13 CTRP2 0.2192 11.6031 -2.3746 43.1036
OVK18 GDSC1 0.3161 8.4443 -3.9383 25.6403
COV362 CTRP2 0.3168 5.8296 -0.149 39.3731
OV56 CTRP2 0.3807 4.8749 0.1389 38.4211
OV56 GDSC1 0.4084 3.3701 -1.3331 9.4682
Caov-4 GDSC1 2.8051 4.9339 -0.6647 0.6742
⏷ Show the Full List of 79 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 14 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IST-Mes1 CTRP2 -4.6905 -1.4058 -4.6928 70.9705
IST-Mes2 CCLE -4.5211 -0.9735 -4.5515 63.6848
NCI-H28 GDSC1; CCLE -4.4913 -3.1046 -4.4913 64.3296
NCI-H28 CTRP2 -4.1608 -1.8092 -4.161 67.9097
IST-Mes1 GDSC1; CCLE -3.9227 -1.8754 -3.9238 59.4083
MPP 89 GDSC1; CCLE -3.9073 -0.9007 -3.9247 59.0334
NCI-H2452 GDSC1; CCLE -3.6047 -0.1047 -3.6543 56.3709
MSTO-211H CTRP2 -3.5594 4.364 -4.0301 60.7589
NCI-H2052 GDSC1; CCLE -3.2772 -0.6604 -3.2894 53.8501
MSTO-211H GDSC1; CCLE -3.1445 -1.2647 -3.1458 52.7642
NCI-H2452 CTRP2 -3.0702 3.3176 -3.3127 59.1526
JL-1 CTRP2 -2.7521 -0.0855 -2.7538 58.5613
ACC-MESO-1 CTRP2 -2.2744 -0.455 -2.2744 55.4193
NCI-H2052 CTRP2 -1.5695 2.5546 -1.6334 50.6988
⏷ Show the Full List of 14 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
VCaP CTRP2 -7.7816 -6.2307 -7.7816 91.3053
VCaP GDSC1 -6.5943 -4.4011 -6.5969 80.0574
22Rv1 GDSC1; CCLE -6.2509 -4.0119 -6.2511 78.6513
LNCaP clone FGC CTRP2 -5.9963 -2.5127 -5.9979 78.7121
22Rv1 CTRP2 -5.662 -3.0912 -5.6621 77.5405
DU145 GDSC1; CCLE -4.8834 -1.6618 -4.8969 66.8294
LNCaP clone FGC GDSC1 -4.1921 -0.3118 -4.4884 52.2958
PC-3 GDSC1; CCLE -4.0601 1.3124 -4.3184 58.7751
DU145 CTRP2 -3.2168 5.3543 -3.8828 58.6524
PaCa-3 CTRP2 2.127 12.4341 -0.8034 34.553
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC1; CCLE -4.1015 -1.8184 -4.1038 60.8871
YD-15 CTRP2 -3.2795 -1.2373 -3.2796 62.1036
A-253 CTRP2 -2.4624 3.3766 -2.6704 55.9106
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1 -5.7542 -4.5836 -5.7542 72.2509
Cancer Drug Sensitivity Data Curated from 65 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Fu97 CTRP2 -7.9734 -4.6885 -7.9736 89.2525
ECC10 CTRP2 -7.7348 -4.369 -7.7352 88.0244
SNU-16 CTRP2 -7.4742 -6.8466 -7.4742 90.0528
RF-48 GDSC1 -6.8086 -2.7987 -6.8925 76.3581
OCUM-1 GDSC1; CCLE -6.5942 -3.3193 -6.5989 79.5324
NUGC-4 CTRP2 -6.5929 -4.6921 -6.5929 83.8319
GSS CTRP2 -6.5261 -5.8835 -6.5261 83.746
HGC-27 CTRP2 -6.4625 1.9608 -6.7454 73.5803
SNU-620 CTRP2 -6.4523 -5.7747 -6.4523 83.2539
NCI-N87 CTRP2 -6.3474 -4.768 -6.3474 82.4324
SCH GDSC1 -6.2744 -4.4552 -6.2752 77.6007
IM95 GDSC1; CCLE -6.2221 -4.1288 -6.2222 78.5817
IM95 CTRP2 -6.1879 -2.6985 -6.1893 79.8014
23132/87 CTRP2 -5.9669 -3.4478 -5.9669 79.482
RERF-GC-1B GDSC1; CCLE -5.9654 -2.8599 -5.9703 75.3181
NCI-N87 GDSC1; CCLE -5.7428 -3.2684 -5.7437 74.3798
Fu97 GDSC1; CCLE -5.6841 -3.7669 -5.6842 74.3336
ECC10 GDSC1 -5.6426 2.1318 -6.8382 60.5824
OCUM-1 CTRP2 -5.624 -0.5283 -5.654 74.5545
HSC-39 GDSC1 -5.556 -4.4925 -5.556 69.8359
23132/87 GDSC1 -5.5433 -4.2471 -5.5433 69.5985
SNU-16 GDSC1; CCLE -5.5145 -4.2962 -5.5145 73.1077
NUGC-4 GDSC1; CCLE -5.3405 -1.7608 -5.3599 69.9833
MKN1 GDSC1 -5.1948 -2.9229 -5.2079 64.5874
BGC-823 CCLE -5.0902 -3.0474 -5.0905 69.3092
SNU-1 CTRP2 -5.0262 -0.4401 -5.0468 71.8617
KATO III GDSC1 -4.9876 -1.9613 -5.0577 61.341
AGS GDSC1 -4.9161 -4.014 -4.9161 61.8763
HGC-27 GDSC1; CCLE -4.8816 -0.8958 -4.9281 66.0453
NCC-StC-K140 CTRP2 -4.7325 -0.6121 -4.7444 70.5938
AZ-521 CCLE -4.6126 -2.2357 -4.6145 65.1661
SNU-5 GDSC1 -4.5682 -3.7388 -4.5682 57.53
SNU-216 CTRP2 -4.2985 -1.2697 -4.3001 68.6055
KE-39 CTRP2 -4.2919 -0.2579 -4.3051 67.9826
KE-39 CCLE -4.2072 -2.9339 -4.2072 61.8949
GCIY GDSC1; CCLE -4.1617 -0.9157 -4.1847 61.0094
SH-10-TC CTRP2 -3.9817 -0.7776 -3.9847 66.4918
MKN7 GDSC1; CCLE -3.9535 -0.9947 -3.9688 59.4343
NUGC-3 GDSC1; CCLE -3.8438 -0.0442 -3.9087 58.1597
SNU-601 CTRP2 -3.7291 -0.0061 -3.7397 64.6456
Hs 746.T GDSC1; CCLE -3.6024 -0.6938 -3.6204 56.531
SNU-5 CTRP2 -3.5198 -1.9963 -3.5198 63.7161
SH-10-TC CCLE -3.2241 -1.3745 -3.2251 53.4466
TGBC11TKB GDSC1 -3.2012 -0.4551 -3.3762 41.2331
MKN74 CTRP2 -3.1722 2.6101 -3.3262 60.0831
AGS CTRP2 -3.0683 -2.266 -3.0683 60.7103
GSU CTRP2 -3.056 -2.1671 -3.056 60.6283
MKN1 CTRP2 -2.8376 -1.8988 -2.8376 59.1729
MKN74 CCLE -2.8178 -1.783 -2.8178 49.9646
MKN45 GDSC1; CCLE -2.7295 1.2322 -2.8738 49.2665
NUGC-3 CTRP2 -2.7041 0.2555 -2.7081 58.2116
ECC12 CTRP2 -2.7026 -1.6429 -2.7026 58.2735
SNU-719 CTRP2 -2.4868 6.7152 -3.4575 54.8716
SNU-668 CTRP2 -2.4774 4.6677 -2.9192 55.5331
HuG1-N CTRP2 -2.3049 8.0777 -3.6939 53.7106
MKN7 CTRP2 -2.2082 2.2888 -2.2796 54.727
MKN28 GDSC1 -1.6805 6.3935 -4.6673 36.1612
LMSU CTRP2 -1.6081 4.7921 -2.0014 50.843
SNU-1 GDSC1; CCLE -1.485 1.0355 -1.53 38.6941
Hs 746.T CTRP2 8.3338 9.7251 5.597 0.112
MKN45 CTRP2 8.4522 17.3867 2.233 11.5561
SNG-M GDSC1; CCLE -4.8811 -2.9003 -4.8813 67.5672
SNU-685 CTRP2 -4.632 7.7848 -6.1249 62.0658
SNU-1077 CTRP2 -2.9499 -0.6861 -2.9502 59.9024
SNG-M CTRP2 -2.3664 0.4596 -2.3701 55.996
⏷ Show the Full List of 65 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 27 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KMH-2 GDSC1 -5.891 -3.5814 -5.8985 72.403
IHH-4 GDSC1 -5.5644 -3.7211 -5.5665 69.4137
SW579 CTRP2 -5.503 -1.3654 -5.5112 75.1067
8305C GDSC1; CCLE -5.2512 -2.4509 -5.2551 70.1412
BHT-101 GDSC1 -5.2165 -2.3958 -5.2587 64.1179
ASH-3 GDSC1 -5.0704 -2.6894 -5.0898 63.024
8505C GDSC1; CCLE -5.0352 -2.6755 -5.0364 68.6982
8305C CTRP2 -4.8702 -2.6096 -4.8703 72.5883
TT2609-C02 GDSC1; CCLE -4.8693 -2.1191 -4.874 67.0889
ML-1 [Human leukemia] CTRP2 -4.8474 3.8197 -5.317 66.2476
CGTH-W-1 GDSC1 -4.7181 -3.332 -4.7188 59.3627
8505C CTRP2 -4.7023 -2.5322 -4.7024 71.5092
B-CPAP GDSC1; CCLE -4.4621 -2.3402 -4.4629 63.981
K5 GDSC1 -4.2697 -2.2887 -4.2848 53.7078
FTC-238 CTRP2 -4.2213 -2.064 -4.2213 68.3397
BHT-101 CTRP2 -4.1875 -1.2414 -4.1888 67.9213
WRO GDSC1 -4.0363 -0.3975 -4.298 50.7366
SW579 CCLE -3.6598 -1.2729 -3.6645 57.1216
TT GDSC1 -3.6534 -1.295 -3.7205 46.2818
CGTH-W-1 CTRP2 -3.5125 -1.5344 -3.5125 63.6556
B-CPAP CTRP2 -3.4591 -1.1529 -3.4594 63.278
FTC-133 CTRP2 -3.2177 -0.1938 -3.221 61.5766
ML-1 [Human leukemia] GDSC1 -3.1948 3.3175 -4.7197 44.3526
CAL-62 GDSC1 -3.1258 -0.4849 -3.2877 40.2806
HTC-C3 GDSC1 -2.2005 0.5 -2.546 30.1043
TT2609-C02 CTRP2 -2.1449 4.2963 -2.4834 53.8994
TT CTRP2 -1.4143 3.3996 -1.5552 49.7101
⏷ Show the Full List of 27 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 68 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H3118 GDSC1 -7.6506 -4.9738 -7.655 87.3754
PE/CA-PJ49 CTRP2 -7.2863 -5.2666 -7.2863 87.8974
PCI-06A GDSC1 -6.6919 -4.8056 -6.6925 81.8872
BICR 78 GDSC1 -6.1829 -4.3574 -6.1839 76.5715
SAT [Human HNSCC] GDSC1 -6.1379 -3.2822 -6.1603 73.7315
PCI-38 GDSC1 -5.9706 -2.1869 -6.0729 69.8324
SCC-9 GDSC1; CCLE -5.9096 -2.5219 -5.9191 74.4823
Ca9-22 GDSC1 -5.8618 -4.6234 -5.8618 73.534
PCI-04B GDSC1 -5.7944 -3.4424 -5.8036 71.2617
JHU-022 GDSC1 -5.7701 -2.1115 -5.8691 68.248
SKN-3 GDSC1 -5.7444 -3.2722 -5.7576 70.4868
SAS GDSC1 -5.6898 -3.567 -5.695 70.4885
SCC-4 CTRP2 -5.6181 -0.5865 -5.646 74.61
SCC-25 CTRP2 -5.5494 -0.1607 -5.5925 73.7597
OSC-20 GDSC1 -5.4083 -1.5231 -5.5641 64.354
JHU-011 GDSC1 -5.361 -3.0645 -5.3729 66.4763
BICR 18 CTRP2 -5.3489 -0.8066 -5.3655 73.7518
BICR 22 GDSC1 -5.3275 -3.1459 -5.3365 66.2364
PCI-15A GDSC1 -5.2955 -2.3991 -5.341 64.8665
CAL-27 GDSC1; CCLE -5.0947 -3.6604 -5.0947 69.4951
PE/CA-PJ15 GDSC1 -5.0136 -2.6665 -5.0324 62.3991
KOSC-2 GDSC1 -5.0003 -2.6355 -5.0201 62.2263
LB771-HNC GDSC1 -4.965 -2.7794 -4.978 61.9772
BHY GDSC1 -4.9233 -2.1285 -4.9739 60.8969
HO-1-N-1 GDSC1 -4.7115 -3.2601 -4.7125 59.2682
BICR 22 CTRP2 -4.6936 0.5753 -4.7474 69.2324
BICR 6 CTRP2 -4.6417 -2.3344 -4.6417 71.0794
Hs 840.T CCLE -4.5322 0.2475 -4.6645 62.6365
DOK GDSC1 -4.4977 -2.9766 -4.4997 56.6041
SCC-25 GDSC1 -4.4721 -1.3389 -4.5882 55.5938
SCC-15 GDSC1 -4.4064 -1.9022 -4.4518 55.1804
OSC-19 GDSC1 -4.404 -1.8082 -4.458 55.1117
BICR 56 CTRP2 -4.3242 -0.2986 -4.3369 68.1868
BICR 31 GDSC1 -4.3022 -0.1707 -4.6439 53.3064
PE/CA-PJ41 (clone D2) CTRP2 -4.1546 0.5428 -4.1906 66.6409
HO-1-u-1 GDSC1 -4.1139 -2.8325 -4.1149 51.8479
Detroit 562 CTRP2 -4.0046 0.7762 -4.0471 65.6789
BICR 31 CTRP2 -3.9891 0.9105 -4.0381 65.494
YD-10B CTRP2 -3.9877 0.0345 -4.0029 66.1073
YD-8 CTRP2 -3.9305 -0.0577 -3.9427 65.839
SNU-1076 CTRP2 -3.8115 -0.9639 -3.8128 65.5056
SNU-1214 CTRP2 -3.7722 -1.1527 -3.7729 65.3007
HSC-4 GDSC1 -3.6916 -0.0397 -4.0119 47.1409
CAL-33 GDSC1 -3.6835 -1.8485 -3.7028 46.531
FaDu GDSC1; CCLE -3.655 -1.3107 -3.6591 57.0871
BICR 10 GDSC1 -3.4769 -0.1451 -3.7501 44.7161
CAL-27 CTRP2 -3.4477 -1.1665 -3.4479 63.2043
BB30-HNC GDSC1 -3.4258 -1.1228 -3.5004 43.5535
Detroit 562 GDSC1; CCLE -3.4114 0.2007 -3.4766 54.7714
SNU-46 CTRP2 -3.4012 0.0444 -3.4087 62.6567
SCC-9 CTRP2 -3.3914 0.7595 -3.4168 62.3061
PE/CA-PJ34 (clone C12) CTRP2 -3.3583 0.8261 -3.3854 62.0819
HSC-3 GDSC1 -3.356 -1.7008 -3.3726 42.4613
BHY CTRP2 -3.3374 0.0204 -3.344 62.272
PCI-30 GDSC1 -3.3284 2.2752 -4.4214 44.796
SNU-899 CTRP2 -3.2162 0.3997 -3.2281 61.4069
SNU-1066 CTRP2 -3.1498 -0.2642 -3.1522 61.1576
KON GDSC1 -3.0158 -1.6694 -3.0242 38.1753
HSC-3 CTRP2 -2.9523 0.0138 -2.9557 59.8446
PE/CA-PJ15 CTRP2 -2.9009 5.3315 -3.5328 57.2759
FaDu CTRP2 -2.8551 2.2108 -2.9503 58.5619
HSC-2 GDSC1; CCLE -2.5773 -1.6085 -2.5773 47.8989
BB49-HNC GDSC1 -2.4517 2.4267 -3.5673 36.6889
SNU-1041 CTRP2 -2.3997 3.5684 -2.6321 55.5011
HSC-4 CTRP2 -2.3289 2.6759 -2.4415 55.3617
CAL-33 CTRP2 -2.2325 1.5985 -2.2625 55.0004
BICR 16 CTRP2 -1.1245 6.4886 -1.9049 48.2212
HSC-2 CTRP2 -0.7071 1.1948 -0.7079 44.9817
⏷ Show the Full List of 68 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 43 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KU-19-19 GDSC1 -6.3294 -5.1482 -6.3294 79.2323
647V CTRP2 -5.6644 -2.8144 -5.6647 77.3542
RT-112 GDSC1; CCLE -5.5915 -2.7168 -5.5952 72.7614
UM-UC-1 CTRP2 -5.5788 1.627 -5.763 71.4038
CAL-29 GDSC1 -5.1756 -3.7239 -5.1761 65.0056
5637 CTRP2 -5.0617 -2.1843 -5.0623 73.5606
5637 GDSC1; CCLE -5.0502 -3.5942 -5.0502 69.1119
KU-19-19 CTRP2 -5.0293 -2.6308 -5.0294 73.5801
647V GDSC1 -4.9378 -2.3052 -4.975 61.2339
SCaBER CCLE -4.7921 -1.7447 -4.8021 66.2442
TCCSUP GDSC1; CCLE -4.6324 -3.2163 -4.6324 65.5378
TCCSUP CTRP2 -4.6166 -1.9844 -4.6169 70.8172
U-BLC1 CTRP2 -4.5942 -3.8665 -4.5942 70.876
BFTC-905 GDSC1 -4.5796 -2.1135 -4.6158 57.2302
253J CTRP2 -4.4135 -0.9987 -4.4172 69.1451
SCaBER CTRP2 -4.3857 -0.6654 -4.3928 68.7803
HT-1197 GDSC1; CCLE -4.3843 -2.609 -4.3844 63.3829
KMBC-2 CCLE -4.1694 -2.9099 -4.1694 61.5701
JMSU-1 CCLE -4.0708 -1.876 -4.0725 60.6451
RT-112 CTRP2 -4.0429 0.5229 -4.075 66.0722
SW1710 GDSC1 -3.9846 -2.074 -4.0016 50.2309
T24 GDSC1; CCLE -3.9188 -1.1605 -3.9289 59.2164
RT-4 GDSC1; CCLE -3.9026 -1.1062 -3.9137 59.0685
HT-1376 GDSC1; CCLE -3.8967 -2.5303 -3.8967 59.2277
HT-1197 CTRP2 -3.8144 -2.4961 -3.8144 65.6802
UM-UC-3 GDSC1; CCLE -3.7464 -0.4913 -3.7773 57.6146
SW780 GDSC1; CCLE -3.6846 -1.2187 -3.6904 57.3184
639V GDSC1; CCLE -3.5146 -1.5067 -3.5161 55.9267
VM-CUB-1 CTRP2 -3.464 -0.2373 -3.4685 63.1329
JMSU-1 CTRP2 -3.2694 -1.4322 -3.2695 62.0441
CAL-29 CTRP2 -3.2511 4.4092 -3.7049 59.3678
BC-3C CTRP2 -2.8744 0.6196 -2.886 59.2295
KMBC-2 CTRP2 -2.5531 1.6615 -2.596 56.9776
J82 GDSC1; CCLE -2.5028 0.535 -2.5535 47.3402
SW1710 CTRP2 -2.4883 1.4583 -2.5191 56.6282
HT-1376 CTRP2 -2.1611 0.4048 -2.1632 54.6502
RT-4 CTRP2 -1.8916 0.3246 -1.8924 52.8674
J82 CTRP2 -1.8234 4.5707 -2.1892 52.075
639V CTRP2 -0.6626 3.5386 -0.7739 44.8947
T24 CTRP2 -0.6515 8.8071 -2.1676 46.2199
UM-UC-3 CTRP2 0.1743 4.9073 -0.091 39.8139
BFTC-905 CTRP2 1.5827 7.8594 0.582 32.8799
253J-BV CTRP2 7.8667 9.3043 5.571 0.261
⏷ Show the Full List of 43 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NEC8 GDSC1 -8.2528 -6.2465 -8.253 93.7432
TC-YIK GDSC1 -8.2226 -5.0799 -8.2315 89.196
PA-1 GDSC1 -7.6679 -6.3029 -7.6679 92.5346
HT-3 GDSC1 -6.2732 -4.0478 -6.2772 76.6864
SKG-IIIa GDSC1 -6.2543 -4.1399 -6.2571 76.7465
NCC-IT GDSC1 -5.8853 -4.6531 -5.8854 73.8249
NT2-D1 GDSC1 -5.8575 -3.6892 -5.8626 72.3015
DSH1 GDSC1 -5.7615 -3.0597 -5.7834 70.216
HEY GDSC1 -5.6812 -3.0151 -5.7028 69.4302
C-33 A GDSC1 -5.221 -4.2756 -5.221 65.6816
PWR-1E GDSC1 -5.1296 -3.4025 -5.1318 64.2982
SW954 GDSC1 -5.0137 -3.2953 -5.0161 62.8923
Ca Ski GDSC1 -4.9103 -2.5054 -4.934 61.141
BPH-1 GDSC1 -4.7656 -1.744 -4.847 58.9131
JAR GDSC1 -4.7255 -3.9431 -4.7255 59.4961
JEG-3 GDSC1 -4.6849 -3.987 -4.6849 58.9892
OMC-1 [Human cervical carcinoma] GDSC1 -4.6725 -1.9627 -4.7256 58.1374
OVCA420 GDSC1 -4.5638 -2.7384 -4.5703 57.3442
HEC-1 GDSC1 -4.4961 -3.6808 -4.4961 56.6286
C-4-I GDSC1 -4.3477 -1.762 -4.4032 54.46
DoTc2 4510 GDSC1 -4.2274 -1.435 -4.3133 52.999
MS751 GDSC1 -4.2108 -1.2907 -4.3156 52.7739
OVCA433 GDSC1 -3.9498 -2.8275 -3.9502 49.8003
ACC-OV7 GDSC1 -3.8102 -1.2552 -3.8925 48.1762
LB831-BLC GDSC1 -3.7094 -1.727 -3.7374 46.8716
KGN GDSC1 -3.6368 -1.2263 -3.7114 46.0994
UWB1.289 GDSC1 -3.501 -0.9805 -3.6016 44.5432
SiSo GDSC1 -3.397 -1.6368 -3.4188 42.9937
SW962 GDSC1 -3.3045 -1.8883 -3.3117 41.7729
ME-180 GDSC1 -3.2955 -2.0934 -3.298 41.636
OVMIU GDSC1 -3.1233 -1.3064 -3.1589 39.6643
HeLa CTRP2 -3.0533 -0.7692 -3.0537 60.588
SKN GDSC1 -3.0125 -1.0781 -3.0662 38.385
SW756 GDSC1 -3.0033 0.4045 -3.3887 39.7521
CAL-39 GDSC1 -2.2726 1.4973 -2.9925 33.0401
SiHa GDSC1 -1.7245 1.4374 -2.3911 26.3947
JHOS-3 GDSC1 -1.5717 2.1224 -2.5312 26.4515
HeLa GDSC1 -1.3247 -0.976 -1.3247 16.9865
OV17R GDSC1 1.7556 10.7299 -3.9557 21.2367
PEO1 GDSC1 2.244 9.4788 -2.9975 15.1806
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Panobinostat (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Panobinostat caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [10]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Panobinostat and Ivosidenib. Acute myeloid leukaemia [2A60] [10]
Arn-509 DMT81LZ Major Increased metabolism of Panobinostat caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [10]
Gilteritinib DMTI0ZO Major Increased risk of prolong QT interval by the combination of Panobinostat and Gilteritinib. Acute myeloid leukaemia [2A60] [10]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Panobinostat and Oliceridine. Acute pain [MG31] [10]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Panobinostat and Ivabradine. Angina pectoris [BA40] [11]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Panobinostat and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [10]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Panobinostat and Levalbuterol. Asthma [CA23] [12]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Panobinostat and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [13]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Panobinostat and Eribulin. Breast cancer [2C60-2C6Y] [10]
Tucatinib DMBESUA Major Decreased metabolism of Panobinostat caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [14]
Palbociclib DMD7L94 Moderate Decreased metabolism of Panobinostat caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [14]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Panobinostat and Bosutinib. Breast cancer [2C60-2C6Y] [10]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Panobinostat and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [10]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Panobinostat and Olodaterol. Chronic obstructive pulmonary disease [CA22] [15]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Panobinostat and Vilanterol. Chronic obstructive pulmonary disease [CA22] [12]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Panobinostat and Regorafenib. Colorectal cancer [2B91] [16]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Panobinostat and Ardeparin. Coronary thrombosis [BA43] [16]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Panobinostat and Pasireotide. Cushing syndrome [5A70] [10]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Panobinostat and Osilodrostat. Cushing syndrome [5A70] [10]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Panobinostat caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [14]
MK-8228 DMOB58Q Moderate Decreased metabolism of Panobinostat caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [14]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Panobinostat and Danaparoid. Deep vein thrombosis [BD71] [16]
Vortioxetine DM6F1PU Major Increased risk of bleeding by the combination of Panobinostat and Vortioxetine. Depression [6A70-6A7Z] [17]
OPC-34712 DMHG57U Major Decreased metabolism of Panobinostat caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [18]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Panobinostat and Deutetrabenazine. Dystonic disorder [8A02] [10]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Panobinostat and Ingrezza. Dystonic disorder [8A02] [10]
Stiripentol DMMSDOY Moderate Decreased metabolism of Panobinostat caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Panobinostat caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [10]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Panobinostat and Cannabidiol. Epileptic encephalopathy [8A62] [11]
Tazemetostat DMWP1BH Moderate Increased metabolism of Panobinostat caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [10]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Panobinostat and Avapritinib. Gastrointestinal stromal tumour [2B5B] [16]
Boceprevir DMBSHMF Major Decreased metabolism of Panobinostat caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [14]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Panobinostat and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [10]
Cobicistat DM6L4H2 Major Decreased metabolism of Panobinostat caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Panobinostat and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [10]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Panobinostat and Teriflunomide. Hyper-lipoproteinaemia [5C80] [19]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Panobinostat and BMS-201038. Hyper-lipoproteinaemia [5C80] [20]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Panobinostat caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [14]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Panobinostat caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [14]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Panobinostat and Polyethylene glycol. Irritable bowel syndrome [DD91] [21]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Panobinostat and Denosumab. Low bone mass disorder [FB83] [22]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Panobinostat and Crizotinib. Lung cancer [2C25] [10]
Ceritinib DMB920Z Major Decreased metabolism of Panobinostat caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [14]
PF-06463922 DMKM7EW Moderate Increased metabolism of Panobinostat caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [10]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Panobinostat and Osimertinib. Lung cancer [2C25] [10]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Panobinostat and Lumefantrine. Malaria [1F40-1F45] [16]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Panobinostat and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [23]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Panobinostat and Idelalisib. Mature B-cell leukaemia [2A82] [24]
IPI-145 DMWA24P Moderate Decreased metabolism of Panobinostat caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [14]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Panobinostat and Acalabrutinib. Mature B-cell lymphoma [2A85] [16]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Panobinostat and Ibrutinib. Mature B-cell lymphoma [2A85] [16]
Arry-162 DM1P6FR Major Increased risk of bleeding by the combination of Panobinostat and Arry-162. Melanoma [2C30] [16]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Panobinostat and Vemurafenib. Melanoma [2C30] [25]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Panobinostat and LGX818. Melanoma [2C30] [10]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Panobinostat caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [10]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Panobinostat and Tecfidera. Multiple sclerosis [8A40] [26]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Panobinostat and Siponimod. Multiple sclerosis [8A40] [16]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Panobinostat and Fingolimod. Multiple sclerosis [8A40] [27]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Panobinostat and Ocrelizumab. Multiple sclerosis [8A40] [28]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Panobinostat and Ozanimod. Multiple sclerosis [8A40] [10]
Fedratinib DM4ZBK6 Major Increased risk of bleeding by the combination of Panobinostat and Fedratinib. Myeloproliferative neoplasm [2A20] [16]
Ruxolitinib DM7Q98D Major Increased risk of bleeding by the combination of Panobinostat and Ruxolitinib. Myeloproliferative neoplasm [2A20] [16]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Panobinostat and Entrectinib. Non-small cell lung cancer [2C25] [10]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Panobinostat and Nepafenac. Osteoarthritis [FA00-FA05] [29]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Panobinostat and Rucaparib. Ovarian cancer [2C73] [10]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Panobinostat and Triclabendazole. Parasitic worm infestation [1F90] [10]
Abametapir DM2RX0I Moderate Decreased metabolism of Panobinostat caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [30]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Panobinostat and Macimorelin. Pituitary gland disorder [5A60-5A61] [31]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Panobinostat and Lefamulin. Pneumonia [CA40] [10]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Panobinostat and Degarelix. Prostate cancer [2C82] [10]
Enzalutamide DMGL19D Major Increased metabolism of Panobinostat caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [10]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Panobinostat and Relugolix. Prostate cancer [2C82] [10]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Panobinostat and Golimumab. Rheumatoid arthritis [FA20] [32]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Panobinostat when combined with Anthrax vaccine. Sepsis [1G40-1G41] [33]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Panobinostat caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [14]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Panobinostat caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [11]
Larotrectinib DM26CQR Moderate Decreased metabolism of Panobinostat caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [14]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Panobinostat and LEE011. Solid tumour/cancer [2A00-2F9Z] [10]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Panobinostat and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [10]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Panobinostat and Pitolisant. Somnolence [MG42] [10]
Plicamycin DM7C8YV Major Increased risk of bleeding by the combination of Panobinostat and Plicamycin. Testicular cancer [2C80] [16]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Panobinostat caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [34]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Panobinostat and Apixaban. Thrombosis [DB61-GB90] [16]
Brilinta DMBR01X Moderate Decreased metabolism of Panobinostat caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [14]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Panobinostat and Lenvatinib. Thyroid cancer [2D10] [10]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Panobinostat and Cabozantinib. Thyroid cancer [2D10] [10]
Elagolix DMB2C0E Moderate Increased metabolism of Panobinostat caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [10]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Panobinostat and Betrixaban. Venous thromboembolism [BD72] [16]
⏷ Show the Full List of 89 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 1 E00263 19700 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Gelatin E00630 Not Available Other agent
Magnesium stearate E00208 11177 lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Colcothar yellow E00436 518696 Colorant
Haematite red E00236 14833 Colorant
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Panobinostat 10 mg capsule 10 mg Oral Capsule Oral
Panobinostat 15 mg capsule 15 mg Oral Capsule Oral
Panobinostat 20 mg capsule 20 mg Oral Capsule Oral
Panobinostat Lactate eq 10mg base capsule eq 10mg base Capsule Oral
Panobinostat Lactate eq 15mg base capsule eq 15mg base Capsule Oral
Panobinostat Lactate eq 20mg base capsule eq 20mg base Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Panobinostat FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7489).
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
6 Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
7 Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med. 2015 Oct 8;6:269-76.
8 Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Rev Clin Pharmacol. 2016;9(1):35-48.
9 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
10 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
11 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
13 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
14 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
15 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
16 Cerner Multum, Inc. "Australian Product Information.".
17 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
18 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
19 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
20 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
21 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
22 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
23 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
24 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
25 Canadian Pharmacists Association.
26 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
27 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
28 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
29 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
30 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
31 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
32 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
33 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
34 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.